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Abstract 
 
Oxidative damage has been suggested to play a key role in the pathogenesis of 
atherosclerosis and other cardiovascular disease (CVD). Increased free radical 
production induced by oxidative stress can oxidise low density lipoproteins, activates 
platelets, induces endothelial dysfunction and disturbs glucose transport by 
consuming endogenous antioxidants. Supplementation with antioxidants is known to 
decrease markers of oxidative stress. 
  
Using a combination, of in vitro and in vivo experimental models, the primary aims of 
the studies undertaken for this thesis were to examine if different hydrophilic and 
lipophilic antioxidants could improve risk factors leading to thrombosis, 
atherosclerosis and other cardiovascular diseases through mechanism involved in 
platelet activity and glucose uptake by skeletal muscle myotubes in response to 
induced oxidative stress in normal healthy population.  
 
The phenolic compounds of olive leaves and olive oils in the Mediterranean diet have 
been associated with a reduced incidence of heart disease. The active phenolic 
compounds in this extract (oleuropein) are part of the secoiridoid family, known for 
their capacity to scavenge H2O2. Accordingly, the aim of the first study described in 
Chapter Two was to determine the most effective dose of olive leaf extract that would 
attenuate platelet activity in healthy human subjects. Five different concentrations of 
extract of Olea europaea L. leaves ranging from 5.4 µg/mL to 54 µg/mL were 
investigated. Platelet function at increasing concentrations of oleuropein was 
determined through measures of platelet aggregation and ATP release from 
activated platelets. Blood analysis (n=11) revealed a significant dose-dependant 
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reduction in platelet activity with olive extract concentrations of 54 µg/mL (p<0.001). 
ATP Release, a measure of platelet dense granule release, showed a similar pattern 
to the results for platelet activity (p=0.02). The results from this study demonstrate 
that olive leaf polyphenols derived from Olea europaea L. leaves inhibited in vitro 
platelet activation in healthy, non-smoking male subjects. 
 
In chapter three, the effect of exercise and antioxidant supplementation on platelet 
function was compared between trained and sedentary individuals. The purpose of 
the exercise bout was to induce oxidative stress. In this randomised, double-blind, 
placebo-controlled cross over study, 16 healthy, 8 trained and 8 sedentary male 
subjects had their diet supplemented for one week with 236 mg/day of cocoa 
polyphenols. All subjects underwent 1 hr of sub maximal cycling at 70% of VO2max 
before and after 1 week of supplementation. Baseline platelet count and ATP release 
increased significantly (p<0.05) after exercise in all subjects. Baseline platelet 
numbers in the trained were higher than in the sedentary (235±37 vs. 208±34 x109/L, 
p<0.05), whereas platelet activation in trained subjects was lower than sedentary 
individuals (51±6 vs. 59±5%, p<0.05). Seven days of cocoa polyphenol 
supplementation did not change platelet activity compared to the placebo group. In 
conclusion, trained subjects had decreased activation of stimulated platelets 
compared to the sedentary subjects and short term cocoa polyphenol 
supplementation did not decrease platelet activity in response to exercise 
independent of prior training status.  
 
Results of epidemiological studies show an inverse relationship between vitamin E 
intake and coronary disease. The activity of vitamin E is derived primarily from alpha-
tocopherol (α-tocopherol) and gamma-tocopherol (γ-tocopherol). The third study 
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undertaken for this thesis and described in chapter four determined the effect of 5 wk 
of either 100 mg/d or 200 mg/d γ-T supplementation on thrombotic risk markers 
including platelet function, lipid profile and the inflammatory marker C-reactive protein 
(CRP). In a double-blinded parallel study design 14 healthy subjects consumed 100 
mg/day and 13 consumed 200 mg/d of γ-tocopherol while 12 received placebo 
(soybean capsules with less than 5 mg/d γ-tocopherol). Fasting pre and post 
supplementation blood samples were analysed for various markers of inflammation, 
platelet activity and lipid profile. Blood γ-tocopherol concentrations increased 
(p<0.05) relative to dose during the intervention period. Both groups receiving active 
ingredients showed lower platelet activation after supplementation (p<0.05). Subjects 
consuming 100 mg/d γ-tocopherol had decreased LDL cholesterol, platelet 
aggregation and mean platelet volume (MPV) (all p<0.05). Little effect of γ-tocopherol 
was observed on other parameters (i.e. CRP). These data suggest that γ-tocopherol 
supplementation may have a permissive role in decreasing the risk of thrombotic 
events by improving lipid profile and reducing platelet activity. 
 
The final study described in chapter five was undertaken to determine the effect of 
oxidative stress and gamma tocopherol treatment on glucose transport and insulin 
signalling in cultured rat L6 muscle cells. L6 myotubes were incubated with either 100 
µM or 200 µM gamma tocopherol for 24 h and exposed to oxidative stress for 1 hr by 
treating with 100 mU/mL glucose oxidase (H2O2 generating system). 2-deoxy-D-[
3H]-
glucose uptake by myotubes and the phosphorylation of Akt and AS160 on amino-
acid residues that are important for insulin signalling were assessed. One hour 
treatment with 100 mU/mL glucose oxidase significantly decreased glucose uptake 
both with and without 100 nM insulin stimulation (p<0.05). Pre-treatment with 100 µM 
and 200 µM gamma tocopherol partially protected cells from the effect of glucose 
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oxidase, whereas 200 µM gamma tocopherol restored both basal and insulin 
stimulated glucose transport to control levels. Glucose oxidase-induced oxidative 
stress did not impair basal or insulin stimulated phosphorylation of Akt or AS160, but 
200 µM gamma tocopherol improved insulin-stimulated phosphorylation of these 
proteins. These observations indicate that gamma tocopherol improves the free 
radical defence system and partially prevents adverse effect of oxidative stress on 
insulin signalling in rat L6 muscle cells.  
 
In summary, the results from the studies undertaken for this thesis provide evidence 
that antioxidant supplementation maintains normal platelet function, exerts a positive 
effect on blood lipid profile and improves glucose uptake in normal healthy 
asymptomatic population as well as under conditions of induced oxidative stress. 
Antioxidants including foods rich in cocoa, olive and gamma tocopherol have the 
potential to combat oxidative stress induced cardiovascular diseases. 
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Cardiovascular Disease, Oxidative stress and Antioxidants 
 
Cardiovascular disease is one of the major health problems in advanced as well as 
developing nations (Barbato and Tzeng, 2004). According to World Health 
Organisation statistics, coronary heart disease currently kills more than 7 million 
people and costs more than $258 billion in health care services, medications, and 
lost productivity each year worldwide (Mackay and Mensah, 2004). Oxidative stress 
plays a central role in the pathogenesis of a wide range of cardiovascular related 
diseases, including thrombosis, Type II diabetes, hypercholesterolaemia and 
atherosclerosis.  
 
Extensive research during the last 25 years has demonstrated that free radicals, 
particularly, reactive oxygen species and reactive nitrogen species play a cardinal 
role in the damage caused by oxidative stress. There is increased oxidative stress 
due to conditions such as diabetes (Baynes, 1991), which impairs muscle glucose 
uptake (Blair et al., 1999), by damaging the blood vessel walls by oxidising lipids and 
in turn activating platelets resulting in thrombosis and other cardiac complications  
(Boullier et al., 2001). The results of many epidemiological studies have 
demonstrated a protective role of antioxidants through a diet rich in fruits and 
vegetables against the development and progression of atherosclerosis and other 
cardiovascular disease (CVD) (Genkinger et al., 2004, Kushi et al., 1996, Law and 
Morris, 1998, Rimm et al., 1996). This review presents an overview of our current 
knowledge regarding the oxygen free radicals involved in cardiovascular 
complications, and the preventive endogenous as well as exogenous antioxidant 
defence.  
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In this regard, several naturally occurring products have received considerable 
scientific enquiry because of their potential antioxidant activity. Consuming a diet rich 
in natural antioxidants has been associated with prevention from and/or treatment of 
atherosclerosis. Bioactive components of food, which are of special interest, include 
the vitamin E, cocoa and olive polyphenols, all of which have antioxidant properties. 
Antioxidant therapy is believed to be effective in the early stages of atherosclerosis 
by preventing low density lipoproteins (LDL) oxidation and the oxidative lesion of 
endothelium. The preventive effect of dietary antioxidants can be illustrated by an 
improvement in impaired lipid profile and platelet dysfunction seen in response to 
oxidative stress. Understanding the effect of oxidative stress on cardiovascular 
disease, in relation to platelet activity and glucose uptake by skeletal muscle, may 
open new horizons for allowing effective dietary intervention strategies to recover 
normal homeostasis and to prevent diet-related implications. 
 
1.1 Pathogenesis of atherosclerosis 
Atherosclerosis is a disease of large and medium sized arteries that results in 
progressive accumulation of lipids within intima of smooth muscle cells. Growth of 
atherosclerotic lesions causes narrowing of blood vessel lumen and affects the 
arterial wall (Ross, 1993, Vardaxis, 1994, Chan, 1998).  Atherosclerosis is a 
multifactorial disease and accounts for the majority of premature deaths in Western, 
developed countries (Poulter, 1999).  
 
Early asymptomatic atherosclerosis lasting for years is characterised by the 
deposition of intracellular and extra cellular lipids and by the appearance of 
macrophages and T-lymphocytes in the vessel intima. As macrophages and smooth-
muscle cells below the endothelial cells accumulate lipids, they acquire a foamy 
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appearance visible as fatty streaks (Figure 1.1) (Davies and Woolf, 1993). These flat, 
fatty lesions may be transformed into raised fibro lipid plaques and ultimately into a 
fibroatheroma, which has a characteristic microanatomy of a core of extra cellular 
lipid covered on the luminal side by a thick fibrous cap. Surrounding the core are 
lipid-laden foam cells, while ischaemia in the necrotic core initiates angiogenesis 
(Paul et al., 2004). 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1.1 oxidative modifications of low density lipoproteins (LDL) and its implication in 
atherosclerotic development. Native LDL is oxidatively modified by reactive oxygen species 
(ROS) generated by resident vascular cells (e.g. smooth muscle cells, macrophages, 
endothelial cells etc) in the subendothelial space. Oxidised LDL promoted foam cell 
formation, endothelial dysfunction and injury, eventually leading to the development and 
progression of atherosclerotic plaques.  
 
Native LDL is oxidatively modified by reactive oxygen species (ROS) generated by 
resident vascular cells (e.g. smooth muscle cells, macrophages, endothelial cells etc) 
in the subendothelial space (Figure 1.1). Oxidised LDL promotes foam cell formation, 
endothelial dysfunction eventually leading to the development and progression of 
Lumen 
Endothelial Injury 
Intima 
Subendothelial 
space 
Media 
Adventitia 
LDL 
ROS 
Foam Cell 
Oxidatively 
modified LDL 
Developing atherosclerotic 
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atherosclerotic plaques. Although oxygen is a crucial molecule to all living organisms, 
it can be toxic for endothelial cells. Perturbations to oxidative balance can lead to 
induction of oxidative stress by ROS. Collectively, cells residing in atherosclerotic 
lesions may produce ROS that contribute to oxidative modification of LDL, which in 
turn is believed to promote foam cell formation (Figure 1.1), accelerating the 
progression and growth of atherosclerotic plaques (Rein et al., 2000b, Kuhn and 
Chan, 1997, Juliano et al., 1997, Hertog and Hollman, 1996, Chan, 1998).  
 
The mural thrombosis is a critical part of the later progression of the atherosclerotic 
lesion and is probably the major event leading to vascular occlusion. If the thrombus 
is not occlusive, it becomes incorporated into the plaque and is organized by invading 
macrophages, endothelial cells, and smooth muscle cells, thereby further 
compromising the lumen of the vessel. The sequence of fissure, thrombus formation, 
organization, and incorporation into the plaque may occur repeatedly (Bult et al., 
1999). Once compensatory vascular remodelling becomes inefficient, this type of 
plaque may cause narrowing of the lumen. The ultimate stage, the complicated 
plaque, may arise either from a fissure in the fibrous cap, or from intraplaque 
haemorrhage. Antioxidant agents have been proposed to arrest these effects (Chan, 
1998).  
 
Thromboembolic events following plaque fissure are a major cause of clinically 
manifest acute ischaemic syndromes. Major mechanisms leading to coronary 
thrombosis include frank rupture of a plaque's fibrous cap, intraplaque haemorrhage, 
and superficial erosion of the endothelium. Plaque rupture occurs when the 
mechanical stresses in the fibrous cap exceed a critical level that the tissue can 
withstand (Lee and Libby, 1997). Furthermore, activated macrophages in 
  10
atherosclerotic lesions kill smooth muscle cells in their vicinity either by lytic damage 
leading to necrosis or by inducing apoptosis (Kockx, 1998, Kockx et al., 1996a, Kockx 
et al., 1996b). As smooth muscle cells are central to the biosynthesis and 
maintenance of the fibrous cap, their numbers may become insufficient to repair the 
degradation. Well known accelerating risk factors for atherosclerosis include 
hypercholesterolaemia, hypertension, diabetes, and smoking. 
 
 In hypercholesterolaemia induced atherosclerosis, a causal role has been attributed 
to oxidized-LDL (ox-LDL) (Witztum, 1993, Hamilton, 1997). Oxidation of lipoproteins 
flooding the intima may result from the production of reactive oxygen intermediates, 
particularly peroxynitrite (ONOO–) or from 15-lipoxygenase activities in the endothelial 
cells. Ox-LDL is, in turn, cytotoxic to endothelial cells due to the metal-catalysed 
production of free radicals from lipid hydroperoxides contained in the modified 
lipoprotein particle (Thomas et al., 1993). Ox-LDL accumulates in the endothelial 
cells, intima, and smooth muscle cells and is chemotactic for monocytes and T-
lymphocytes. Newly formed antigenic determinants (epitopes) in ox-LDL elicit cell-
mediated and humoral immune responses (Libby and Hansson, 1991). Minimally 
modified LDL stimulates the endothelial and smooth muscle cells to secrete 
monocyte chemotactic protein-1 and growth factors involved in the differentiation and 
proliferation of monocytes. 
 
 In addition, ox-LDL may, synergistically with cytokines, promote mononuclear 
leukocyte adhesion to the endothelium through the induction of vascular cell 
adhesion molecules and intercellular cell adhesion molecules (Khan et al., 1995, 
Kume et al., 1992). Monocyte-derived macrophages internalize ox-LDL through 
scavenger receptors. As these receptors are not down regulated by the intracellular 
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cholesterol level, massive cholesterol accumulation occurs and the macrophages 
transform to foam cells (Jialal et al., 2004). Ox-LDL cholesterol increases the 
synthesis of caveolin-1 (Cav-1; the principal structural protein in caveolae that binds 
cholesterol), which inhibits production of nitric oxide (NO) by inactivating endothelial 
nitric oxide synthase (eNOS) (Kinlay et al., 2001). Conversely, normal release of NO 
prevents oxidative modification of LDL cholesterol (Rubbo et al., 2002). Under 
healthy conditions, low concentrations of NO are continuously involved in a variety of 
physiological functions, which include the regulation of blood pressure, blood flow 
and platelet aggregability (Moncada et al., 1991). However, in atherosclerosis there is 
impaired generation of NO in the vascular endothelium, leading to vascular 
dysfunction (Harrison, 1997). This probably co-exists with the expression of inducible 
nitric oxide synthase (iNOS) in the plaque, generating excessive amounts of NO and 
leading to an interaction with oxygen-derived radicals, generation of ONOO–, and 
further impaired vascular function.  
 
1.1.1 Endothelial Dysfunction 
The major risk factors for atherosclerosis include hypercholesterolaemia, 
hypertension, diabetes, and smoking (Cai and Harrison, 2000). These conditions are 
associated with endothelial dysfunction, which itself is associated with reduced 
endothelial generation of NO. Vascular injury begins with endothelial dysfunction and 
activation. Endothelium dysfunction is considered as an early indicator of 
atherosclerosis, and precedes atherosclerotic plaque. Endothelium dysfunction can 
be detected at both the conduit and microvascular levels in patients with coronary risk 
factors, even though there may be no evidence of structural coronary artery disease 
(McFadden et al., 1991, Vrints et al., 1992a, Vrints et al., 1992b).  
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Endothelial dysfunction is at the core of microvascular complications, and correlates 
closely with insulin resistance (Cleland et al., 2000). Endothelial dysfunction might 
itself contribute to platelet hyperactivity and to insulin resistance (Scherrer and 
Sartori, 2000); indeed, it could precede the onset of insulin resistance in populations 
at risk for diabetes (Caballero et al., 1999). A direct role of insulin in microvascular 
physiology is also recognized. For example, insulin stimulates the expression and 
activation of endothelial NO synthase (Lazar et al., 1995). In addition to being a 
potent vasodilator, NO is a key vasoprotective agent influencing pathogenic 
pathways including oxidative stress, smooth-muscle proliferation, lipid per oxidation, 
and chemo attraction and monocyte adhesion. Even though insulin is a potent 
vasoactive hormone, under basal circumstances it has limited net hemodynamic 
effects (Vicent et al., 2003). 
 
Endothelial dysfunction of the microvasculature has also been associated with 
exercise-induced myocardial ischaemia in patients without haemodynamically 
significant CAD of the epicardial arteries, suggesting that endothelial dysfunction of 
the microcirculation may contribute to ischaemia when myocardial oxygen demand is 
increased (Zeiher et al., 1995). The enhanced ROS production at sites of injury has 
multiple consequences for endothelial function. Increased adhesion molecule 
expression attracts monocytes, which transmigrate and become macrophages and 
produce much higher amounts of ROS. Reactive oxygen species can also promote 
vascular leakage, which is important in ischemia–reperfusion-induced vascular injury 
and the induction of inflammatory responses. 
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1.1.1.1 Role of Inflammation in CVD 
Epidemiological and clinical studies have linked inflammatory markers to the risk of 
future cardiovascular events (Ridker, 2004). White blood cells are part of the body's 
immune defense system, and their levels are an indirect measure of inflammation in 
the body. Studies examining links between CVD and inflammation have focused 
mostly on a molecule called C-reactive protein (CRP) as a marker of inflammation. 
CVD is associated with elevated markers of systemic inflammation, including CRP 
and members of the coagulation cascades. Systemic inflammation has been reported 
to be present before any evidence of myocardial infarction (Lowe, 2001). This 
observation was first interpreted as an inflammatory response to the developing 
atheromatous vascular damage. However, evidence to suggest that systemic 
inflammation causes atherosclerosis is supported by the observation that patients 
with pre-existing inflammatory diseases have a dramatically increased risk of CVD at 
younger ages. Patients with autoimmune diseases such as rheumatoid arthritis and 
lupus have accelerated rates of atherosclerosis (Kao et al.,2003). Elevated CRP 
levels have also been associated with endothelial dysfunction in the form of 
inappropriate vascular constriction/relaxation. CRP has been shown to cause 
induction of endothelial adhesion proteins ICAM-1, VCAM-1, E-selectin, P-selectin, 
and angiotensin type 1 receptor (Pasceri et al., 2000, Verma et al., 2003). 
Additionally, CRP has been implicated in the activation of endothelial NF- B, 
induction of endothelial IL-1ß, PAI-1, IL-6, TNF- , monocyte chemoattractant protein-
1 (MCP-1), endothelin-1, and tissue factor, and inhibition of endothelial NO synthase 
and NO signalling (Labarrere and Zaloga , 2004). 
 
Polyphenols express anti-inflammatory activity by modulation of pro-inflammatory 
gene expression such as cyclooxygenase, lipoxygenase, nitric oxide synthases and 
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several pivotal cytokines, mainly by acting through nuclear factor-kappa B and 
mitogen-activated protein kinase signaling (Yoon and Baek, 2005, Kim et al., 2004 
and stangl et al., 2007). 
 
1.1.2 Endothelial dysfunction and nitric oxide 
 
Nitric Oxide released by the vascular endothelium acts as endothelium-derived 
relaxing factor, and the elucidation of its biosynthetic pathway has opened a whole 
new area in the quest for understanding cardiovascular disease and the ways in 
which it may be prevented (Palmer et al., 1987, Moncada et al., 1991, Feelisch et al., 
1994, de Meyer and Herman, 1997). A reduction in the generation and bioavailability 
of NO has been shown to occur in several disorders, including atherosclerosis. 
 
Endothelium is not merely an inert, single-cell lining covering the internal surface of 
blood vessels, but plays a crucial role in regulating vascular function (Landmesser et 
al., 2004). As the major regulator of vascular homeostasis, the endothelium maintains 
the balance between vasodilation and vasoconstriction, inhibition and stimulation of 
the proliferation and migration of smooth muscle cells, and thrombogenesis and 
fibrinolysis. Endothelial dysfunction leads to the disruption of this balance and causes 
damage to the arterial wall (Landmesser et al., 2004, Luscher and Barton, 1997, 
Kinlay et al., 2001, Davignon and Ganz, 2004). Enhanced superoxide ion (O2
-) levels 
play an important role in the pathophysiology of atherosclerosis (Figure 1.2). For 
instance, O2
- may inactivate NO and diminish its bioavailability, thus inducing 
endothelial dysfunction (Kojda and Harrison, 1999). OONO- induces lipid per 
oxidation and protein nitration and in the process damages vascular cells and wall 
(Figure 1.2).  
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On the other hand O2
- is instrumental in uncoupling of eNOS which results in 
decreased NO production and increased O2
- concentration (Figure 1.2). Increased 
vascular production of ROS promotes the oxidative degradation of the critical eNOS 
cofactor tetrahydrobiopterin (BH4), leading to
 eNOS uncoupling and the consequent 
reduced production of NO and the increased production of superoxide anion from the 
enzyme (Vasquez-Vivar et al., 2002, d'Uscio et al., 2003, Landmesser et al., 2003). 
 
There is indirect evidence to suggest that eNOS uncoupling contributes to endothelial 
dysfunction and increased production of superoxide anion in the oxidative stress of 
ischaemia/reperfusion injury (Huk et al., 1997), hypercholesterolaemia  (Pritchard et al., 
1995), hypertension (Mollnau et al., 2002), diabetes (Guzik et al., 2002), and heart 
failure (Dixon et al., 2003). 
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Figure 1.2 Flow diagram illustrating the multifactorial origin, the intermediate pathways and 
final detrimental consequences of an excess of superoxide anion (O2
-) in the vascular 
system. Adapted from (Zalba et al., 2006).  
 
A defect in NO production or activity has been proposed to be a major mechanism of 
endothelial dysfunction and a contributor to atherosclerosis (Verbeuren et al., 1986, 
Davignon and Ganz, 2004). Impaired production or activity of NO leads to events or 
to actions such as vasoconstriction, platelet aggregation, smooth muscle cells 
proliferation and migration, leukocyte adhesion, and oxidative stress (Endres et al., 
1998). However, endothelial dysfunction is likely to be a multifactorial process. 
Increased vascular production of ROS or superoxide anion has been demonstrated in 
all major conditions predisposing to atherosclerosis (Cai and Harrison, 2000, 
Landmesser and Harrison, 2001, Krotz et al., 2004, Schulz et al., 2004). 
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1.1.3 Role of Platelets in Primary Haemostasis 
Blood platelets play a pivotal role in the development of atherosclerosis and are often 
found at sites of atherosclerotic lesions, closely associated with neutrophils, 
monocytes, macrophages and endothelial cells that produce ROS capable of 
modulating platelet function, via normal cellular metabolism.  
 
Haemostasis is the physiological defence against blood loss and involves tight 
control of clot formation (Figure 1.3) (Schneider et al., 1998). Platelets and 
coagulation factors under normal circumstances do not directly interact with 
endothelial cells lining the vessel walls and only do so when the endothelial lining is 
breached as a consequence of trauma or atherosclerotic plaque disruption 
(Hoffbrand and Pettit, 1993, Veijio et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.3 Integrated concept of cell-based haemostasis. Adapted from (Coller, 1992, Hirsh 
and Weitz, 1999). 
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A delicate balance exists between the interaction of platelets, coagulation factors and 
the fibrinolytic system to maintain haemostatic integrity. The net result of these 
interactions is stabilisation of the platelet plug by fibrin, followed by cross-linking of 
fibrin by factor XIIIa to form an insoluble fibrin clot. 
 
Vascular breach releases tissue factor (TF) and factor VIIa from endothelial cells 
(initiating release of clotting factors and activation cascade leading to blood clot 
formation). These factors activate factor X and V, which in turn lead to thrombin 
formation necessary for platelet activation and to convert fibrinogen to fibrin (Figure 
1.3). Tissue factor released from damaged endothelial cells activates the extrinsic 
clotting system, generating thrombin, which serves two main functions. The first is the 
primary role of thrombin in conversion of fibrinogen to fibrin and resultant clot 
formation. Secondly, there is self-amplification of thrombin via feedback activation of 
Factors V and VIII. An increase in negatively charged phospholipids (e.g. 
phosphatidylserine) causes membrane modification, permitting assembly of a 
‘tenase’ (Factor X activating complex) and a prothrombinase (prothrombin activating 
complex) (Bennett, 2001, Dracup and Cannon, 1999, Veijio et al., 1999). 
Amplification of thrombin generation enhances platelet activation, aggregation, fusion 
and coagulation (Figure 1.3).  
 
1.1.4 Platelet Physiology: Mechanisms of Platelet Adhesion, Activation and 
Aggregation 
Platelet adhesion, activation and aggregation, constitute the pre-developmental 
stages of an arterial thrombus. At the site of arterial injury, the endothelial barrier is 
broken and platelets adhere to exposed collagen, von Willebrand factor (vWF is a 
large plasma protein and is also present on the surface of platelets serving as a hook 
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to attach platelets to the vascular endothelium and also carries FVIII in the blood) 
and fibrinogen via specific cell receptors (Figure 1.4). Adherent platelets are then 
activated by several independent mediators, including collagen, thromboxane, 
adenosine diphosphate (ADP), and thrombin (Figure 1.4).  
 
 
 
Figure1.4 Key mediators in platelet adhesion, activation & aggregation. See text for further 
details. 
 
Activated platelets degranulate and secrete chemotaxins, clotting factors and 
vasoconstrictors, thereby promoting thrombin generation, vasospasm, and additional 
platelet accumulation. The release of internally stored ADP and thromboxane 
amplifies the process of platelet activation by secondary feedback loops. Activated 
platelets also change shape resulting in cell membrane changes, which are important 
in further aggregation and coagulation (Figure 1.4). Previously inactive GPIIb/IIIa 
receptors on the platelet membrane undergo structural modification and become 
available for fibrinogen and vWF binding. In patients with atherosclerotic stenosis, 
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aggregation and/or amplify all of the three-platelet steps, mediated through vWF and 
ADP-receptors (Figure 1.4). 
 
 
1.1.4.1 Platelet Membrane Glycoproteins: Adhesion Molecules 
Platelet membrane glycoproteins (GP) are now known to be adhesion molecules 
identified in other cell types in the late 80’s (Pischel et al., 1988, Roth, 1992, Phillips 
et al., 1988, Hsu-Lin et al., 1984). They are present on the platelet surface or inserted 
into the alpha-granule membrane (Figure 1.4), and play a key role in normal platelet 
adhesion or aggregation. 
 
1.1.4.2 Membrane Glycoproteins in Platelet Physiology 
Physiological agonists that may be present at the vascular lesion site include 
thrombin, collagen and ADP (Ruggeri, 1994). In response to these agonists, a 
spectrum of specific activation dependent modifications of platelet antigens can be 
detected. This process leads to an intracellular signal transduction cascade involving 
ion fluxes and activation of the cytoskeleton. The end result is secretion of 
endosomes, which causes reorganisation and conformational changes of surface 
receptor expression through inside-out signalling. Platelet activation leads to an 
altered expression of already constitutively expressed surface glycoproteins (figure 
1.5). Increased numbers of GPIIb-IIIa complexes and reduced numbers of GPIb-IX 
complexes result from bi-directional trafficking of these glycoproteins between the 
cell surface, the surface-connected canalicular system and intracellular storage 
(Michelson and Barnard, 1987). 
 
Inside-out signalling leads to conformational changes of GPIIb-IIIa complexes, 
exposing conformation-dependent activation epitopes with high affinity for their 
ligands (Sims et al., 1991).  
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Figure 1.5 Platelet glycoprotein interactions (for description see text) 
 
The release reaction of platelets is associated with the neo-expression of α-granule 
glycoproteins such as CD62P or CD63. Measuring the expression of these antigens 
on circulating platelets reflects not only the activation state of the platelets, but also to 
what extent secretion has occurred. 
 
Platelets adhere to other platelets through fibrinogen attachment at GPIIb-IIIa 
receptors on platelet surface and form a plug at site of injury by their GPIb receptors 
interacting with von Willebrand factor (vWF), while GPVI, GPIa/IIa and GPIV interact 
with collagen released from the damaged endothelial wall (Figure 1.5).  
 
1.1.4.3 Adhesion 
 
Trauma or plaque disruption causes platelet adherence to exposed subendothelial 
structures (e.g. collagen), via interactions with glycoprotein GP Ib-IX-V complex on 
the platelet membrane and von Willebrand factor (vWF) under conditions of high 
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shear stress (Fredrickson et al., 1998). Interactions mediated by GP Ia/IIb occur 
under conditions of low shear stress. Occupancy of this receptor by collagen, 
activates platelets (Figure 1.5), thereby causing fusion and exocytosis of alpha and 
dense granule contents (e.g. ADP, ATP, serotonin, calcium (Ca2+), fibronectin, β-
thromboglobulin, thrombospondin, P-selectin etc.) (Lefkovits et al., 1995, Puri and 
Colman, 1997, Schneider et al., 1998, Hirsh and Weitz, 1999). Adhesion causes 
microtubule depolymerisation, pseudopodia extension and loss of the discoid 
appearance of platelets (Reed et al., 2000). 
 
1.1.4.4 Activation 
 
During agonist-induced platelet activation, energy-dependent fusion of both alpha 
and dense granules with the plasma membrane and expression of granule proteins 
(e.g. P-selectin), promotes and propagates platelet adhesion to endothelial and white 
cells (Schneider et al., 1998). Binding of thrombin to its receptor, protease activated 
receptor (PAR) activates the alpha unit of Gq (G protein) via tyrosine 
phosphorylation, thereby producing inside-out signalling by activating phospholipase 
Cβ (PLCβ) (Shattil et al., 1998). Activated PLCβ hydrolyses phosphatidylinositol 4,5 
bisphosphate (PIP2), producing the second messengers inositol 1,4,5 triphosphate 
(1,4,5-IP3) and sn-1, 2 diacylglycerol (sn-1, 2 DAG) (Figure 1.6).   
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Figure1.6 Cascade of events leading to platelet activation, aggregation and its inhibition 
upon agonist binding to its specific cellular receptor, tyrosine kinase (TK) activation 
subsequently phosphorylates and activates phospholipase C (PLC). This cleaves 
phosphatidylinositol 4,5 bisphosphate (PIP2), resulting in the generation of inositol 1,4,5 
triphosphate (1,4,5-IP3) and sn-1, 2 diacylglycerol (Sn-1, 2 DAG). Coupled with increased 
Ca2+, the latter activates protein kinase C (PKC.) As a result, PLA2 is activated and 
arachidonic acid (AA) is produced. Activation of cyclooxygenase (COX) produces the 
proaggregatory agent thromboxane (TXA2), which functions to stimulate tyrosine kinase (TK) 
activity via autocrine signalling, dense granule release, further platelet activation and 
aggregation. Prostaglandin (PGI2) released from endothelial COX inhibits adenylate cyclase, 
thereby increasing intracellular cAMP levels, decreasing Ca2+ levels, thus inhibiting platelet 
aggregation. Prostaglandin produced by platelets can inhibit aggregation via activation of 
platelet adenylate cyclase. Human platelet adenylate cyclase is stimulated by prostaglandin 
E1 (PGE1). Adapted from (Shattil et al., 1998) 
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IP3 mobilises Ca
2+ from internal stores. Sn-1, 2 DAG and the released Ca2+ activate 
protein kinase C (PKC) and subsequently promote PLA2 activation (Shattil et al., 
1998, Schneider et al., 1998, Savage et al., 2001). Hydrolysis of membrane 
phospholipids via PLA2 activation yields arachidonic acid (AA) and thromboxane A2 
(TXA2) (Figure 1.6) (Savage et al., 2001). PKC has been implicated in assisting the 
exocytosis of substances from platelet granules (Selheim et al., 2000). 
 
Synergism between PKC and Ca2+ levels help regulate platelet exocytosis of 
microparticles (e.g. AA), which are metabolised via the cyclooxygenase (COX) 
pathway (Reed et al., 2000). Arachidonate is oxygenated via platelet COX to produce 
prostaglandins D2 (PGD2), G2/H2 (PGG2/H2) and thromboxane (TXA2). Despite PGD2 
inhibition of platelet activation, the net effect of platelet activation by PGG2/H2 and 
TXA2 is greater (Holmsen, 1994). In contrast, endothelial COX produces PGI2. 
Platelet lipid per oxidation products (12-hydroxyeicosatetraenoate or 12 HETE) 
undergo further processing by neutrophils and red cells to yield certain 
hydroeicosatetraenoic acids of altered biological function. It has been hypothesized 
that transcellular transfer of AA may amplify or modulate the consequences of 
platelet activation, possibly extending to other cells in the growing thrombus (Barry et 
al., 1997).  
 
As thrombus grows there is further release of ADP, serotonin and TXA2 stimulating 
coagulation. ADP released from platelet granules recruits additional platelets, 
causing platelet cohesion and thrombus growth promotion (Veijio et al., 1999, 
Hoffbrand and Pettit, 1993, Hirsh and Weitz, 1999). Platelet activation and secretion 
of growth factors stimulate smooth muscle cell proliferation, thereby accelerating 
atherosclerosis (Schneider et al., 1998). Collagen-induced platelet activation 
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releases H2O2, which activates tyrosine kinase (TK), consequently resulting in 
phosphorylation and activation of phospholipase Cγ2 (PLCγ2) (Pignatelli et al., 1998). 
This results in an increase in intracellular Ca2+ levels, accumulation of PtdIns 3,4P2 
and irreversible platelet aggregation (Savage et al., 2001, Selheim et al., 2000). 
 
1.1.4.5 Aggregation 
Collagen and thrombin stimulation of platelet prostaglandin (PG) production results in 
the production of TXA2. TXA2 triggers the release reaction by lowering cyclic 
adenosine monophosphate levels (cAMP). Additional ADP and TXA2 released 
stimulate secondary aggregation. Endothelial PGI2 inhibits the release reaction by 
increasing cAMP concentrations, thereby regulating platelet aggregation (Figure 1.5) 
(Hoffbrand and Pettit, 1993, Bennett, 2001). ADP, TXA2, thrombin and collagen bind 
to specific receptors, trigger signalling pathways and act synergistically in activating 
and modulating GP IIb/IIIa receptors for fibrinogen and vWF (Hirsh and Weitz, 1999, 
Phillips et al., 2001). Each fibrinogen molecule binds two platelets, creating a 
bridging network of platelet aggregates. Fibrin incorporation produces a fibrin clot 
(Hirsh and Weitz, 1999, Veijio et al., 1999, Bennett, 2001). 
 
1.1.5 Atherosclerotic Involvement in Arterial Thrombosis 
Atherosclerosis causes coronary insufficiency, manifesting clinically as coronary 
artery disease (CAD). Dietary factors have been implicated as potential risks for 
atherosclerotic development. As a result, dietary modification has been one of the 
strategies adopted in secondary prevention and management of this disease 
(Hoffbrand et al., 1999, Vardaxis, 1994). Oxidative stress induced by free radicals 
has been associated with atherosclerotic development (Berliner et al., 1995). 
Atherosclerosis increases with age. However, it frequently escapes detection 
because of its insidious and asymptomatic behaviour. Of particular concern is the 
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socioeconomic impact inflicted by the high incidence of mortality and morbidity 
associated with atherosclerosis and its complications (Ross, 1993). 
 
Atheroma-narrowed arteries are characterised by high levels of shear stress capable 
of inducing platelet activation and aggregation (Schneider et al., 1998). Plaque 
content, integrity of the fibrous cap, and haemodynamic stress determine the 
occurrence of plaque fissure (Vardaxis, 1994, Veijio et al., 1999). Although 
endothelial cells synthesize anti-thrombotic and anti-haemostatic substances, 
thrombosis ensues when prothrombotic stimuli (e.g. vWF, collagen and TF) and 
mitogens are released during plaque ulceration. Interaction of thrombogenic 
substances with blood elements results almost immediately in thrombin-mediated 
platelet dependent thrombosis (Gallus, 1986, Hoffbrand and Pettit, 1993, Hoffbrand 
et al., 1999, Veijio et al., 1999). After reaching a considerable mass and under high 
shear conditions induced by stenotic lesions, thromboembolism occurs (Hoffbrand et 
al., 1999). 
 
1.1.5.1 The relationship of CVD to reactive oxygen species  
Reactive oxygen species or free radical formation is associated with the normal 
natural metabolism of aerobic cells. The oxygen consumption inherent in cell growth 
leads to the generation of a series of oxygen free radicals. The interaction of these 
species with molecules of a lipid nature produces new radicals, hydroperoxides and 
different peroxides (Aust and Sringen, 1982). Lipid peroxidation in biological 
membranes is a highly destructive phenomena produced when reactive oxygen 
species and free radicals attack the double bonds of polyunsaturated fatty acids 
(PUFAs) to yield lipid peroxides (Halliwell et al., 1995). 
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This group of radicals, either superoxide, hydroxyl or lipid peroxides, may interact 
with biological systems in a prominent cytotoxic manner (Bors et al., 1990b, Bors et 
al., 1990a). These free radicals have been suggested to lead to oxidation of low 
density lipoprotein (LDL), which in turn promotes foam cell formation and accelerates 
the progression of atherosclerosis (Kuhn and Chan, 1997) (Figure 1.7). 
 
 
Figure1.7 Foam cell formation in early atherosclerosis. Reactive oxygen species (ROS) 
produced by other cells during normal cell metabolism modifies native low density lipoprotein 
(LDL) into oxidised LDL which then causes monocyte chemotaxis, foam cell formation, 
endothelial cell damage and dysfunction. The deposition of foam cells brings about the fatty 
streaks which forms the initial atherosclerotic lesion. ROS, reactive oxygen species; LDL, 
low-density lipoprotein. Adapted from (Kuhn and Chan, 1997) 
 
The sensitivity of LDL to oxidative stress depends on an appropriate balance 
between the amount of PUFAs and antioxidant concentrations. The LDL particle itself 
contains various antioxidants (e.g. tocopherols, β-carotene, ubiquinol 10, 
criptoxantine) which protect it from non-enzymatic oxidation (Esterbauer et al., 1992). 
Data from Visioli et al. suggests that massive lipid peroxidation only occurs when the 
antioxidant pool is depleted from the LDL particle (Visioli and Galli, 1994).  
 
Antioxidants have been proposed to chelate the hydrogen peroxide (H2O2) produced, 
bringing about a decrease in platelet aggregation (Figure 1.8) (Pignatelli et al., 1998).  
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Figure1.8 Cascade of arachidonic acid metabolism. Following stimulation by agonist like 
collagen, there is burst of the hydrogen peroxide (H2O2) (Pignatelli et al., 1998). H2O2 
activates the enzyme phospholipase C that brings about arachidonic acid metabolism and 
platelet aggregation. Antioxidants target the H2O2 produced, reducing it, thus preventing 
phospholipase C activation and a decrease in platelet aggregation. Adapted from (Scalbert 
and Williamson, 2000). 
 
1.2 Oxidative stress 
Oxidative stress is defined in general as excess formation and/or insufficient removal 
of highly reactive molecules such as ROS and reactive nitrogen species (RNS) 
(Turko et al., 2001, Maritim et al., 2003). Oxidation reactions are an essential part of 
normal metabolism as oxygen is the ultimate electron acceptor in the electron flow 
system that produces ATP (Davies, 1993). Problems may arise when electron flow 
and energy production become uncoupled so that oxygen free radicals, that is, ROS, 
are produced (Nohl et al., 2005).  
 
ROS are continuously produced within the cell as a result of mitochondrial electron 
transfer processes or as bioproducts of the enzymes xantine oxidase, lipoxygenases 
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and cycloxygenases (Szocs, 2004). They can also be generated as a consequence 
of the intracellular metabolism of foreign compounds, toxins or drugs by cytochrome 
P450, monoxygenases, or because of exposure to environmental factors such as 
excessive iron salts or UV irradiation (Ichihashi et al., 2003). External sources of 
oxidative stress include ageing, smoking, alcohol, environmental pollution, all of 
which increase production of free radicals more than required for normal body 
metabolism and endogenous antioxidants are not enough to neutralise them. 
 
Other sources of ROS are macrophages and neutrophils that contain enzymes, such 
as NADPH oxidase complex, which are able to generate superoxide radicals and 
hydrogen peroxide (Rosen et al., 1995). ROS, thus play different positive roles in 
vivo, being involved in energy production, phagocytosis, cell growth and intercellular 
signalling regulation. However, they may also be highly damaging, as they can attack 
biological macromolecules, namely, lipids, proteins and DNA, induce oxidation and 
cause membrane damage, enzyme inactivation and DNA damage (Halliwell and 
Gutteridge, 1999, Valko et al., 2004). When the level of ROS exceeds the antioxidant 
capacity of the cell, the intracellular redox homeostasis is altered and oxidative stress 
ensues (Halliwell, 1999). Under these conditions external source of antioxidants may 
be required to combat oxidative stress related damages.  
 
ROS include free radicals such as superoxide (•O2
-), hydroxyl (•OH), peroxyl (•RO2), 
hydroperoxyl (•HRO2
-) as well as nonradical species such as hydrogen peroxide 
(H2O2) and hydrochlorous acid (HOCl) (Turko et al., 2001, Evans et al., 2002a). RNS 
include free radicals like nitric oxide (•NO) and nitrogen dioxide (•NO2
-), as well as 
nonradicals such as peroxynitrite (ONOO-), nitrous oxide (HNO2) and alkyl 
peroxynitrates (RONOO) (Evans et al., 2002a, Turko et al., 2001). Of these reactive 
  30
molecules, •O2
-, •NO and ONOO- are the most widely studied species and play 
important roles in the diabetic cardiovascular complications.  
 
1.2.1 What causes oxidative stress? 
Oxidative stress is the damage to cells caused by oxidation. All forms of life maintain 
a reducing environment within their cells. The cellular redox environment is 
preserved by enzymes that maintain the reduced state through a constant input of 
metabolic energy. Disturbances in this normal redox state can cause toxic effects 
through the production of peroxides and free radicals that damage components of the 
cell such as lipids and DNA. Other conditions, such as toxic substance exposure, 
smoking and asphyxia, obesity, diabetes and excessive sudden exercise, likewise 
induce oxidative stress. The oxidized lipid products generated as a consequence of 
these conditions are highly reactive and cause damage to cells and cell membranes. 
Thus, increased oxidative stress accompanied by reduced endogenous defences 
may play a role in the pathogenesis of a number of diseases. 
 
Production of one ROS or RNS may lead to the production of others through radical 
chain reactions. As summarised in Figure 1.9, •O2
- is produced by one electron 
reduction of oxygen by several different oxidases including NAD(P)H oxidase, 
xanthine oxidase, cyclooxygenase and even eNOS under certain conditions as well 
as by the mitochondrial electron transport chain during the course of normal oxidative 
phosphorylation, which is essential for generating ATP (Evans et al., 2003, 
Griendling and FitzGerald, 2003a, Griendling and FitzGerald, 2003b, Taniyama and 
Griendling, 2003). Under normal conditions, •O2
- is quickly eliminated by antioxidant 
defence mechanisms. •O2
- is dismutated to H2O2 by manganese superoxide 
dismutase (Mn-SOD) in the mitochondria and by copper (Cu)-SOD in the cytosol 
(Evans et al., 2003).  
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Figure 1.9 Generation of reactive species in diabetes. Highlighted are some of the most 
important ROS and RNS in vascular cells. Oxygen is converted to •O2
- via the activation of 
enzymatic and nonenzymatic pathways, which is then dismutated to H2O2 by SOD. H2O2 can 
be converted to H2O by catalase or glutathione peroxidase (GSH-Px) or to 
•OH after reaction 
with metals like iron (Fe). Glutathione reductase regenerates glutathione (GSH). In addition, 
•O2
- reacts rapidly with •NO to form ONOO-. Adapted from (Johansen et al., 2005)  
 
H2O2 is converted to H20 and O2 by glutathione peroxidase (GSH-Px) or catalase in 
the mitochondria and lysosomes, respectively. H2O2 can also be converted to the 
highly reactive •OH radical in the presence of transition elements such as iron (Figure 
1.9). 
 
In vasculature, NO is normally produced from L-arginine by eNOS (Turko et al., 2001, 
Evans et al., 2002). NO mediates endothelium-dependent vasorelaxation through its 
action on guanylate cyclase in vascular smooth muscle cells. •NO also displays 
antiproliferative properties and inhibits platelet and leukocyte adhesion to vascular 
endothelium (Turko et al., 2001, Evans et al., 2002)., •NO is therefore considered a 
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vasculoprotective molecule. However, •NO easily reacts with superoxide, generating 
the highly reactive molecule ONOO-, and triggering a cascade of harmful events 
(Turko et al., 2001, Evans et al., 2002, Vega-Lopez et al., 2004). Its chemical 
environment, i.e. presence of •O2
-, determines whether •NO exerts protective or 
harmful effects. 
 
1.2.2 Why are reactive species bad? 
While ROS are generated under physiological conditions and are involved to some 
extent as signalling molecules and defence mechanisms, in phagocytosis, neutrophil 
function, and shear-stress induced vasorelaxation, excess generation in oxidative 
stress has pathological consequences including damage to proteins, lipids and DNA. 
ROS can stimulate oxidation of LDL, and ox-LDL, which is not recognised by the LDL 
receptor, can be taken up by scavenger receptors in macrophages leading to foam 
cell formation and atherosclerotic plaques (Boullier et al., 2001). Several damaging 
pathways in diabetes including accelerated formation of advanced glycation end 
products (AGE), polyol pathway, hexosamine pathway and PKC, all of which have 
been proven to be involved in micro- and macrovascular complications, can be 
activated by O2
-. In endothelial cells, H2O2 mediates apoptosis and pathological 
angiogenesis (Taniyama and Griendling, 2003). Furthermore, •O2
- immediately reacts 
with •NO generating cytotoxic ONOO- and this reaction itself has several 
consequences. First, ONOO- alters function of biomolecules by protein nitration as 
well as causing lipid peroxidation (Turko et al., 2001). For example, potassium 
channels, which regulate the vasorelaxation response, are inhibited by nitration (Liu 
and Gutterman, 2002, Liu et al., 2002b). Increased levels of nitrotyrosine are 
associated with apoptosis of myocytes, endothelial cells and fibroblasts in diabetes 
(Turko et al., 2001). Second, ONOO- causes single-strand DNA breakage, which in 
turn activates nuclear enzyme poly (ADP-ribose) polymerase (PARP) (Soriano et al., 
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2001). Third, it decreases •NO bioavailability causing impaired relaxation and 
inhibition of the antiproliferative effects of •NO (Maritim et al., 2003). Furthermore, 
ONOO- oxidizes tetrahydrobiopterin (BH4), an important cofactor for NOS, and 
causes uncoupling of NOS, which produces •O2
- instead of •NO (Maritim et al., 2003). 
ROS-induced peroxidation of membrane lipids alters the structure and the fluidity of 
biological membranes, which ultimately affects function (Maritim et al., 2003, 
Griendling and FitzGerald, 2003a, Griendling and FitzGerald, 2003b, Taniyama and 
Griendling, 2003). All these pathological modifications contribute to the pathogenesis 
of vascular dysfunction. 
 
1.2.3 Oxidative stress and Coronary Heart Disease 
Considerable research interest has developed in determining the role of free radical–
mediated damage seen in many major medical disorders, in particular CHD and 
diabetes (Baynes, 1991). Oxidative stress results from an imbalance between oxidant 
production (or the formation of reactive oxygen species) and antioxidant defences 
(Maritim et al., 2003). Plasma markers of oxidative stress are increased in CHD, 
diabetes or in the presence of its classic risk factors (Cai and Harrison, 2000, 
Chisolm and Steinberg, 2000, Harrison et al., 2003, Maritim et al., 2003) and as a 
result of sudden exercise by sedentary population (Belviranli and Gokbel, 2006).  
 
1.2.3.1 Oxidative stress due to Diabetes lead to Coronary Heart Disease 
Type 2 diabetes mellitus (T2DM) induces a number of cardiovascular disorders, 
including platelet hyperactivity and hyperaggregability (figure 1.10), that are 
associated to an increased oxidant production (Sobol and Watala, 2000). Oxidative 
stress in T2DM was thought to be a result of free radicals generated during 
autoxidation of glucose (Miyata et al., 1999).  Increased levels of ROS in T2DM was 
implicated to contribute to a hypercoagulable state (Collier et al., 1992),  and there is 
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evidence for the accumulation of oxidation products prior to the development of 
diabetes (Matteucci and Giampietro, 2000). 
 
Metabolic dysfunction occurring in diabetes mellitus is capable, through increased 
oxidative stress, protein kinase C (PKC) and receptor for advanced glycation end 
products (RAGE) activation, of inducing activation of endothelial cells (EC) and 
platelets, which causes a switch toward a pro-thrombotic, pro-inflammatory condition 
and contributes to the pathogenesis of atherosclerosis (Figure 1.10). 
 
Numerous adverse effects on the vascular system are associated with increased 
oxidative stress. The oxidation of vulnerable cell membrane unsaturated lipids (Evans 
et al., 2002) may modulate diverse signal transduction pathways (Harrison et al., 
2003, Suzuki et al., 1997), leading to numerous adverse effects implicated in the 
pathogenesis of atherosclerosis. These include increased expression of cell adhesion 
molecules, induction of proinflammatory pathways, activation of matrix 
metalloproteinase, vascular smooth muscle cell proliferation and death, endothelial 
dysfunction, and lipid peroxidation (LDL oxidation). Apart from the global effects 
associated with increased oxidative stress described above, more specific effects 
also occur. LDL is an important target of oxidation, and oxidative modification of LDL 
is a key step in the pathogenesis of atherosclerosis (Witztum and Steinberg, 2001). 
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Figure 1.10 Platelet activation in type 2 diabetes mellitus. NO, nitric oxide; NF-κB, nuclear 
transcription factor-κB; AP-1, activator protein-1; PGI2, prostacyclin; PAI-1, plasminogen 
activator inhibitor-1Adapted from (Ferroni et al., 2004) 
 
Therefore, as well as the general harmful effects on the vasculature, more specific 
effects may be seen at the lipoprotein level, which are dependent on the properties of 
the lipoprotein molecules. Previous observations suggest that HDL exhibits 
antioxidant properties  (Durrington et al., 2001), and increasing plasma glucose is 
associated with increased oxidative stress (Davi et al., 1999). Interestingly, increased 
triglyceride concentrations are also associated with the increased preponderance of 
small, dense LDL, which is more labile to oxidation (Weinbrenner et al., 2003).  
 
1.2.3.2 Oxidative stress due to sudden exercise lead to Coronary Heart Disease 
Oxidative stress induced by acute strenuous exertion by normally sedentary 
population may interfere with platelet responsiveness by promoting ox-LDL-mediated 
platelet activation and by decreasing platelet-derived nitric oxide bioactivity (Di 
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Massimo et al., 2004). The exact mechanisms and the regulatory pathways involved 
in the effects of acute exercise on platelet function are not completely understood. 
Increases in plasma levels of catecholamines (Ohri et al., 1983, Ikarugi et al., 1997), 
changes in the performance of -adrenergic receptors, increases in platelet count  
(Ohri et al., 1983, Ricci et al., 1991), prostacyclin/thromboxane A2 (PGI2/TxA2) 
imbalance (Drygas, 1988), impaired sensitivity of platelets to PGI2 and nitric oxide 
(Sakita et al., 1997, Drygas, 1988, Kishi et al., 1992, Sinzinger and Fitscha, 1986), 
changes in plasma lipoprotein profile (Agren et al., 1991, Baumstark et al., 1993), 
oxidative stress and changes in antioxidant status are mechanisms  potentially 
involved in exercise-induced platelet responses (Salvemini and Botting, 1993, Wang 
et al., 2000a). Hemodynamic disturbances and increase in shear stress, as a result 
of physical exercise,  (i.e. blood flow) may also play a role in platelet response 
(Ruggeri, 1993, Kroll et al., 1996).  
 The stimulation of cells, including endothelial cells, by shear stress of exercise can 
also lead to the phosphorylation and activation of Akt (Dimmeler et al., 1999). Insulin 
signalling in skeletal muscle is associated with signal transduction at the level of 
insulin receptor substrate 1 (IRS-1) and phosphatidylinositol (PI) 3-kinase (Bjornholm 
et al., 1997, Cusi et al., 2000, Kim et al., 1999, Krook et al., 2000) and glucose 
transport (Krook et al., 2000, Bjornholm et al., 1997, Andréasson et al., 1991). Akt is 
a downstream effector of PI 3-kinase that is directly linked to the regulation of glucose 
transport (Jiang et al., 2003).  
The signalling pathways that mediate insulin’s many actions remain incompletely 
understood, but the following sequence has been well characterized: insulin binds to 
its receptor, leading to receptor autophosphorylation and activation of receptor 
tyrosine kinase, which in turn results in tyrosine phosphorylation of endogenous 
  37
substrates including insulin receptor substrate proteins. These docking proteins 
engage downstream signalling molecules such as phosphatidylinositol (PI) 3-kinase 
(Bergstrom and Hultman, 1966, Taniguchi et al., 2006, Zierath et al., 2000). PI 3-
kinase catalyses the phosphorylation of phosphatidylinositol 4,5-bisphosphate on the 
D3 position of inositol, and the resultant PI 3,4,5-trisphosphate binds and activates 
more distal signalling proteins, including phosphoinositide-dependent kinase-1 and 
Akt, a serine/threonine kinase (Figure 1.11). Akt has been implicated as a key 
signalling protein for several of insulin’s actions, including activation of glycogen 
synthesis, protein synthesis, and GLUT4 translocation to the cell surface, thereby 
increasing glucose transport. 
 
Recently an Akt substrate with molecular weight of 160 kDa (AS160) and a molecular 
signature of a Rab-GAP has been identified as an important regulator of GLUT4 
traffic (Figure 1.11).  Insulin stimulation of skeletal muscle leads to phosphorylation of 
AS160, a process dependent on Akt (Bruss et al., 2005, Bouzakri et al., 2006). 
AS160 is also phosphorylated in response to exercise in human skeletal muscle 
(Deshmukh et al., 2006) and after in vitro contraction in rodent skeletal muscle (Bruss 
et al., 2005, Kramer et al., 2006). Thus, AS160 may be critical point of convergence 
for insulin and exercise mediated glucose uptake in skeletal muscle.   
 
Recently, a novel 160-kDa substrate of Akt has been identified in 3T3L1 adipocytes 
as AS160, a protein containing a Rab GTPase-activating protein (GAP) domain 
(Kane et al., 2002) (Figure 1.11). Phosphorylation of AS160 is required for the insulin-
induced translocation of GLUT4 to the plasma membrane in 3T3L1 adipocytes (Sano 
et al., 2003). 
 
  38
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Insulin signalling that leads to GLUT 4 translocation and glucose uptake. IRS, IR 
substrate; PI3K, phosphatidylinositol-3-kinase; PDK, phosphatidylinositoldependent protein 
kinase; Akt, protein kinase B; AS160, Akt substrate of 160 kDa; GLUT, glucose transporter. 
Adapted from (Hawley and Lessard, 2008). 
 
 
Shear stress stimulates the phosphorylation of eNOS on its Akt-related 
phosphorylation site Ser1177 in humans and Ser1179 in bovines independently of an 
increase in intracellular calcium  (Dimmeler et al., 1999). The phosphatidyl-inositol-3-
kinase (PI3K) and Akt pathway, which causes intracellular calcium-independent 
eNOS phosphorylation and activation, is involved in a shear stress-activated signal 
transduction cascade. 
Increased consumption of oxygen during exercise raises free radical production. 
Endogenous antioxidants respond to this state. However, imbalance in limited 
antioxidants and raised oxidative stress leads to endothelial dysfunction and other 
tissue damage (Figure 1.12). 
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 Figure1.12 Natural antioxidant response to exercise induced oxidative stress 
 
It is thought that regular aerobic exercise increases NO production with up-regulation 
of eNOS gene expression and vascular endothelial growth factor (VEGF)-induced 
angiogenesis and decreases NO inactivation with augmented antioxidant system, 
such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), and 
attenuation of nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide 
phosphate (NADH/NADPH) oxidase activity, leading to an increase in NO 
bioavailability (Higashi and Yoshizumi, 2004).   
 
1.2.4 Human natural defences against deleterious effects of oxidative stress 
To minimize free radical damage, there is a complex endogenous antioxidant 
defence system, including antioxidants within cells, cell membranes and extracellular 
fluids (Jenkins, 1988, Powers and Lennon, 1999, Halliwell and Gutteridge, 1990, 
Sen, 1995). To maintain redox balance against oxidant conditions, blood has a 
central role as it transports and redistributes antioxidants to every part of the body. 
Deleterious effects of physiologically produced free radicals are neutralised by 
antioxidants in the body (Figure 1.12). To cope with an excess of free radicals 
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produced, humans have developed sophisticated mechanisms to maintain redox 
homeostasis.  
 
These protective mechanisms, scavenge or detoxify ROS, block their production, or 
sequester transition metals that are the source of free radicals. They include 
enzymatic and nonenzymatic antioxidant defences produced in the body, namely, 
endogenous defences (Hayes and McLellan, 1999, Sies, 1999), and others supplied 
with the diet, namely, exogenous defences (Benzie, 1999, Yao et al., 2004, Porrini et 
al., 2005).  
 
Several antioxidant enzymes exist that convert ROS into less noxious compounds, 
for example, SOD, catalase, thioredoxin reductase, peroxiredoxin and GPx (Hayes 
and McLellan, 1999, Talalay, 2000, Arnér and Holmgren, 2000) (Matés et al., 1999, 
Chaudière and Ferrari-Iliou, 1999). Collectively, these enzymes provide a first line of 
defence against superoxide and hydrogen peroxides. They are of enormous 
importance in limiting ROS-mediated damage to biological macromolecules, but they 
are not able to be 100% effective, because certain compounds generated by the 
interaction of ROS with macromolecules, are highly reactive. It is then mandatory to 
detoxify these secondary products in order to prevent further intracellular damage, 
degradation of cell components and eventual cell death.  
 
This second line of defence against ROS is provided by enzymes such as GPx, 
glutathione S-transferase (GST), aldo-keto reductase and aldheyde dehydrogenase 
(Armstrong, 1997, Brigelius-Flohè, 1999, Kuhn and Borchert, 2002). The detoxified 
metabolites produced by these enzymes are eliminated from the cell, by efflux pumps 
such as the glutathione S-conjugate transporter (Akerboom and Sies, 1989). Thus, 
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the central role of reduced GSH appears clear in intracellular endogenous antioxidant 
defences, as it is involved in all the lines of protection against ROS (Selheim et al., 
2000). 
 
1.3 Free radicals and antioxidants 
Free radicals are electrically charged molecules, which seek out and capture 
electrons from other substances, to finally neutralise themselves. Although the initial 
attack causes the free radical to become neutralised, another free radical is formed in 
the process, resulting in a chain reaction. Until subsequent free radicals are 
deactivated, thousands of free radical reactions may occur within only a few seconds. 
The term “antioxidant” refers to any molecule capable of stabilizing or deactivating 
free radicals before they attack cells. These are the primary antioxidants. There are 
also molecules deserving the “antioxidant” term, because they act as chelating 
agents binding metal ions (redox activity).  
Free radical formation is associated with the normal natural metabolism of aerobic 
cells. The oxygen consumption inherent in cell growth leads to the generation of a 
series of oxygen free radicals. The interaction of these species with molecules of a 
lipidic nature, produces new radicals: hydroperoxides and different peroxides (Aust 
and Sringen, 1982, Pryor et al., 1982). This group of radicals (superoxide, hydroxyl 
and lipoid peroxides) may interact with biological systems in a clearly cytotoxic 
manner. In this respect, flavonoids, phenols and oleuropeosides have been shown to 
posses an important antioxidant activity towards these radicals, which is principally 
based on the redox properties of their phenolic hydroxyl groups and the structural 
relationships between different parts of their chemical structure (Bors et al., 1990b, 
Visioli et al., 1998a, Bors et al., 1990a, Visioli et al., 1998c) flavonoids, three 
structural groups are important to determine their radical scavenging and/or 
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antioxidative capacity: the o-dihydroxy (catechol) structure in the B-ring, which 
confers greater stability to aroxyl radicals; the 2,3-double bond conjugated with a 4-
oxo function, responsible for electron delocation from the B-ring and the presence of 
both 3- and 5-hydroxyl groups for maximal radical-scavenging capacity and strongest 
radical absorption (Bors et al., 1990b, Bors et al., 1990a). For oleuropeosides and 
the other phenols present in olive leaves, it is mainly the o-dihydroxy (catechol) 
structure present in their moieties, which confers antioxidant properties to these 
compounds.  
 
Obviously, the antioxidant capacity of any phenolic compound will be determined by 
a combination of these structural elements. However, this capacity will not be similar 
or show the same degree of effectiveness towards each of the above mentioned 
radicals, but will depend on the different action of mechanisms which take place in 
each particular case. These mechanisms are influenced by structural factors other 
than those described, such as the presence or absence of glycosidic moieties in the 
polyphenol, the glycosylation site, number and position of the free and sterified 
hydroxyls.  
 
1.3.1 Polyphenols 
Polyphenols are wide variety of compounds that occur in fruits and vegetables, wine, 
tea, extra virgin olive oil, chocolate and other cocoa products. Several polyphenols 
have been demonstrated to have clear antioxidant properties in vitro, and many of 
their biological actions have been attributed to their intrinsic reducing capabilities. 
Polyphenols are commonly found in plants and are comprised of numerous 
subclasses (Kaur and Kapoor, 2001). Important dietary flavonoid subclasses include 
the flavones, flavanones, flavonols, flavanols and anthocyanins, with flavanols being 
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the second most abundant (Hertog et al., 1993, Prior and Cao, 2000, Scalbert and 
Williamson, 2000, Nijveldt et al., 2001). The results of several epidemiological studies 
support an inverse relation between fruit and vegetable intake, as well as the 
consumption of flavonoid-rich beverages and a reduction in heart disease mortality, 
cerebrovascular diseases, common cancers, degenerative diseases and ageing 
(Pignatelli et al., 2000, Prior and Cao, 2000, Rein et al., 2000b, Schramm et al., 
2001). 
 
Flavanols exert their actions via the following mechanisms: 1) Free radical 
scavenging and chelation of metal ions by virtue of AOX activity, 2) Reduction in 
platelet activation and aggregation, 3) Inhibition of lipoxygenase (LPO), 
cyclooxygenase (Casey et al., 2004), phospholipase A2 (PLA2) or stimulation of nitric 
oxide synthase (NOS), 4) Enhancement of prostacyclin (PGI2) release, 5) Anti-
inflammatory action and interaction with biomembranes (de Whalley et al., 1990, 
Terao et al., 1994, Saija et al., 1995, Rice-Evans et al., 1996, Lotito and Fraga, 2000, 
Schewe et al., 2002, Schramm et al., 2001). 
 
Flavanols vary in the number and arrangement of hydroxyl group, degree of acylation 
or glycosylation (Rice-Evans et al., 1996, Bravo, 1998, Hammerstone et al., 2000). 
The chemical structure of polyphenols governs their absorption, metabolism, 
bioavailability, AOX activity and specific interactions with cellular receptors and 
enzymes (Scalbert and Williamson, 2000). Correlation between structure and activity 
is far from clear, because data on their absorption, metabolism and bioavailability are 
scarce and fragmentary (Terao et al., 1994, Saija et al., 1995, Nijveldt et al., 2001). 
Before flavanols can excise their bioactivity, they must first be absorbed, metabolised 
and made bioavailable in vivo. Absorption and metabolism of flavanols largely 
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depends on their structural characteristics, molecular size, solubility and the dosage 
administered. Data available on absorption concentration and metabolism of 
individual polyphenols studied as part of this thesis have been discussed later. Many 
epidemiological studies assessing flavonoid activity are carried out in vitro. This 
cannot be fully extrapolated to the in vivo status of the parent molecule as animal 
models demonstrate the presence of conjugated metabolites in the plasma, raising 
the possibility that some bioactivity may be attributable to their metabolites (Piskula 
and Terao, 1998, Ross and Kasum, 2002). Bioavailability studies investigating tea 
and cocoa polyphenols reveal that relatively low plasma concentrations are 
achievable. However, there is evidence to suggest that high flavonoid concentrations 
may be attained via repeated ingestion (van Het Hof et al., 1999, Scalbert and 
Williamson, 2000).  
 
1.3.2 Structure-Activity Relationship of Polyphenols 
 
Flavonoids are classified based on the degree of oxidation of the oxygen heterocycle 
(Scalbert and Williamson, 2000). They also differ in hydroxylation on the A and C 
rings (C3, C5, C7), and also on the B ring (C3’, C4’, C5’) (Lairon and Amiot, 1999).  
 
 
 
Figure 1.13 Basic diphenylpropane (C6-C3-C6) structure of flavanols. 
 Adapted from (Hollenberg et al., 2004). 
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Flavanols have the diphenylpropane (C6-C3-C6) backbone structure (Figure 1.13) 
varying in the number and arrangement of hydroxyl groups, degree of acylation or 
glycosylation (Rice-Evans et al., 1996, Hammerstone et al., 2000). Basic 
diphenylpropane (C6-C3-C6) "flavan nucleus," is the foundation structure upon which 
flavonoids are constructed. 
 
1.3.3 Cocoa polyphenols (Catechins, epicatechins and procyanidins) 
Whilst most research has concentrated on the polyphenols in tea and red wine, there 
has been increasing interest in cocoa because it is a polyphenol-rich food, containing 
flavan-3-ols such as (-)-epicatechin, (+)-catechin, and their oligomeric counterparts, 
the procyanidins and to a lesser extent, anthocyanins as well as quercetin and its 
glycosides (Fraga et al., 2001, Scalbert and Williamson, 2000, Schewe et al., 2002). 
The discovery that cocoa contained four times more flavonoids than found in 
green/black tea, fuelled even more research as this suggested that cocoa may 
possess greater AOX potential (Arts et al., 1999).  
 
The touted heart-healthy claims of drinking red wine appear to be overstated, as it 
appears to be a poor source of bioavailable flavonols, and there are dangers 
associated with alcohol consumption  (Prior and Cao, 2000, de Vries et al., 2001). 
 
Cocoa contains monomeric flavanols (epicatechin and catechin) and oligomeric 
procyanidins (Hammerstone et al., 1999). Procyanidins, the major polyphenol in 
unfermented cocoa (Figure 1.14), are composed of flavan-3-ol monomers and their 
respective oligomers (Porter et al., 1991). 
 
The results of animal studies show that orally ingested (-)-epicatechin and (+)-
catechin were rapidly absorbed by the intestinal mucosa, conjugated with glucuronic 
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acid by uridine 5’- diphosphoglucuronosyltransferase (UGT), followed by conjugates 
entering the liver, via the portal vein, whereby they are sulfated and methylated by 
phenolsulfotransferase and catechol-O-methyltransferase respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Structure of the flavan-3-ols and their oligomeric counterparts, the procyanidins. 
Proanthocyanidin is composed of three linked subunits. The shaded area represents one 
subunit, which is a flavanol known as Catechin. Epicatechin differs from Catechin only in the 
spatial orientation of its -OH group at position ‘3’ of ‘C’ ring. Adapted from (Hollenberg et al., 
2004). 
 
 
In the kidney, they may also undergo methylation. Finally, these metabolites are 
either excreted in the bile or urine (Piskula and Terao, 1998, Bravo, 1998, Rein et al., 
2000a, Baba et al., 2001, Donovan et al., 2001). Compared with (+)-catechin, (-)-
epicatechin appeared to be absorbed more efficiently as there were more urinary 
metabolites. When put together, they were competitively absorbed (Piskula and 
Terao, 1998). 
 
1.3.4 Olive polyphenols (Oleuropein) 
Antioxidant properties of virgin olive oil are not related to their phenolic content but 
only to the presence of catecholic compounds such as oleuropein and hydroxytyrosol 
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(Visioli et al., 2002a). Olive leaf extract is known to contain a mixture of polyphenolic 
compounds, among them oleuropein and hydroxytyrosol, both of which are readily 
absorbed and bioavailable. The biological activities of olive leaf extract are mainly 
derived from these compounds (Visioli et al., 2002b, Visioli and Galli, 2002). 
Oleuropein is the bitter component of olives and is found in olive oil and leaves, 
mainly as its aglycone form. It is a complex phenol belonging to the secoiridoid class 
of phenolic compounds and constitutes up to 14% in the unripe olives but during 
maturation undergoes hydrolysis to yield simpler molecules including hydroxytyrosol 
(Visioli et al., 1998b).  
 
Figure 1.15 Structure of oleuropein. Adapted from (Konno et al., 1999).  
 
Oleuropein was discovered in 1908 by Bourquelot and Vintilesco, and its structure 
(Figure 1.15) was specified as being that of a heterosidic ester of β-glucosylated 
elenolic acid and 2(3,4,-dihydroxyphenyl) ethanol (Pannizzi et al., 1960). 
 
The antioxidant activity of this compound is attributed to its dihydroxyphenol moiety 
while its secoiridoid glycoside moiety might aid in its transport across the intestine, 
via the paracellular route (Edgecombe et al., 2000, Stupans et al., 2002). Upon acid 
hydrolysis, oleuropein is cleaved at the site indicated to yield hydroxytyrosol (the 
dihydroxyphenol moiety) (Visioli et al., 1994).  
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The antioxidant activity of oleuropein is due mainly to the hydroxytyrosol moiety in its 
structure (Benavente-Garcia et al., 2000). Hydroxytyrosol (Figure 1.16) has been 
shown to exhibit a greater antioxidant potential than oleuropein (de Whalley et al., 
1990, Visioli et al., 1998a, Visioli et al., 1995, Visioli and Galli, 2002, McDonald et al., 
2001). 
 
 
 
Figure 1.16 The structures of hydroxytysol, tyrosol, and caffeic acid which can be 
extracted from the polar fraction of virgin olive oil. Adapted from (de la Puerta et al., 
1999). 
 
  
In contrast, investigations by Saija et al. showed that oleuropein was more effective 
than hydroxytyrosol in protecting against ROS damage in aqueous phase (Saijia et 
al., 1998). It was hypothesized that hydroxytyrosol was only capable of scavenging 
peroxyl radicals near the cell membrane surface, whereas oleuropein could also act 
as a scavenger within membranes. 
 
1.3.4.1 Olive leaf extract versus olives or olive oil 
Olive leaves have been used as medicine in form of boiled tea leaves for about 5000 
years but there is very little scientific evidence relating to the effects of the 
compounds on platelet function and/or thrombosis. Olive leaves stay green all year 
and may be gathered at any time. Olive leaf extract is concentrated liquid made by 
soaking chopped or mashed leaves in a liquid such as alcohol and straining out the 
solid parts. Olive oil is produced in mesocarp cells of fruit and stored in particular type 
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of vacuoles called lipovacuole. Olives are ground to paste and allowed to stand for 
some time for oil drops to agglomerate. Industrial decantation of the paste facilitates 
the process of extraction. This is very expensive and time consuming process, taking 
a long time from harvest to extraction of oil with waiting periods which can expose the 
olive paste to oxygen and light. Oxidation begins immediately upon harvesting and at 
this time fruit’s enzymes are very active, increasingly degrading the endogenous oil 
and increasing acidity with bitterness. Oleuropein is abundant in developing fruit but 
its concentration sharply declines when fruits begin to mature (Malik and Bradford, 
2006). Thus olive oil which is pressed from mature fruits contains very small amounts 
of oleuropein (Bernes-Balbuena et al., 1992, Brenes et al,. 2000, Romero et al., 
2002, Servili et al., 1999). On the other hand, oleuropein is the most abundant 
polyphenol in olive leaves (Braun, 2005, Malik and Bradford, 2006, Benavante-
Garcia, 2000). Olive leaf extract and not olive oil was used in this study due to cost 
and time effectiveness. Leaves are inexpensive due to larger quantities available 
throughout the year. 
 
1.3.5 Gamma tocopherol polyphenols 
 
Vitamin E exists in 8 isoforms as 4 tocopherols and 4 tocotrienols, all of which are 
potent membrane-soluble antioxidants. It is a lipid-soluble antioxidant, which mainly 
accumulates in cell membranes, where it efficiently scavenges superoxide radicals 
and also regenerates other oxidized antioxidants such as dehydroascorbic acid 
(Wang and Jiao, 2000, Ozawa, 1990). Alapha and gamma tocopherols are the 
strongest antioxidants. The antioxidant activity of tocopherols is rooted in their ability 
to donate phenolic hydrogens (electrons) to lipid radicals.  
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Figure 1.17 Vitamin E structure. Adapted from (Jiang et al., 2001). 
 
Tocopherols have a saturated phytyl side chain with 3 chiral centers that are in an R 
configuration (designated as R1, R2 & R3 in Figure 1.17) in the naturally occurring 
forms. Tocopherols differ in the number of methyl groups they have at the 5- and 7-
positions of the chromanol ring. 
 
The biological disposition and retention of γ-tocopherol appear to be regulated by a 
metabolism that is quite different from that of α-tocopherol (Figure 1.18). 
Chylomicron-associated tissue uptake of vitamin E, which occurs before liver 
metabolism, is possibly important for the accumulation of γ-tocopherol in skin, 
adipose, and muscle tissue. This could explain the strong correlation in humans 
between dietary  γ-tocopherol uptake and γ-tocopherol concentrations in these 
tissues (Burton et al., 1998). 
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Figure 1.18 Absorption, transport, and metabolism of α-tocopherol (α -T) and γ-tocopherol 
(γ-T) in peripheral tissues (eg, muscle and adipose). Both α-T and γ-T are similarly absorbed 
by the intestine along with dietary fat and are secreted into chylomicron particles. Some of 
the chylomicron-bound vitamin E is transported to peripheral tissues with the aid of 
lipoprotein lipase. The resulting chylomicron remnants are subsequently taken up by the 
liver. In the liver, most of the remaining α-T but only a small fraction of γ-T is reincorporated 
into nascent VLDLs by α-tocopherol transfer protein (α-TTP). Substantial amounts of γ-T are 
probably degraded by a cytochrome P450 3A–mediated reaction to 2,7,8-trimethyl-2-(ß-
carboxyethyl)-6-hydroxychroman (γ-CEHC). Plasma vitamin E is further delivered to tissues 
by LDL and HDL. γ-CEHC is excreted into urine. Adapted from (Jiang et al., 2001) 
 
Hepatic catabolism of γ-tocopherol appears however, to be responsible for the 
relatively low preservation of γ-tocopherol in plasma and tissues, whereas α-TTP-
mediated α -tocopherol transfer plays a key role in the preferential enrichment of α-
tocopherol in most tissues. It is possible that α-TTP maintains the α-tocopherol 
concentration not only by facilitating its reincorporation into nascent VLDLs but also 
by preventing it from being catabolised (Jiang et al., 2001). This is in contrast with γ-
tocopherol, which appears to be largely degraded by cytochrome P450 once it enters 
the liver. Evidence supporting this possibility includes the findings that both α- and γ-
tocopherol are similarly degraded by cytochrome P450–mediated catabolism in 
cultured hepatocytes (Parker et al., 2000)  and that patients with an  α-TTP defect 
γ-T 
α-T 
Liver 
α-TPP P450 
5 
γ-CECH 
Kidney 
7 
Urinary excretion 
γ-T α-T 
4 
6 
Lipoproteins Plasma 
Lipoprotein 
Lipase 
2 
Chylomicron Chylomicron 
remnants 
1 3 3 
  52
have substantially lower plasma concentrations of α-tocopherol than do individuals 
with no such defect. 
 
1.4 Antioxidants and Cardiovascular Diseases 
1.4.1 Dietary antioxidants and vascular endothelial dysfunction  
The vascular endothelium plays a key role in the regulation of vascular tone by the 
release of vasodilator substances, mainly NO and prostacyclin, and vasoconstrictor 
substances, mainly TxA2, free radicals and endothelin. In particular, in normal 
endothelium, factors such as NO mediate vasolidation, platelet desegregation and 
antiproliferation, and inhibit inflammation; lipoprotein lipase induces lipolysis, and 
tissue plasminogen activator (tPA), von Willebrand factor (vWF), and protein C act as 
thrombolytic agents. In endothelial dysfunction, vasoconstriction, inflammation and 
proliferation mediated by several growth factors (i.e. bFGF and PDGF), as well as 
platelet aggregation mediated by adhesion molecules, such as selectins, and 
thrombosis, result in detrimental functional consequences and adverse long-term 
effects, including vascular remodelling (Fenster et al., 2003). In CVD, endothelium 
dysfunction of the coronary arteries may cause or contribute to myocardial ischemia. 
Numerous clinical trials have been carried out to evaluate dietary interventions, which 
improve endothelial dysfunction, amongst which many look at the potential of the 
antioxidants derived from the diet. The degree of the dysfunction correlates with 
elevated LDL oxidation, dyslipidemias, mainly elevated LDL and decreased high-
density lipoprotein levels, hypertension and diabetes. 
 
1.4.2 Dietary antioxidants and Thrombosis 
Removal of excess ROS or suppression of oxygen free radical generation by 
antioxidants may be effective in preventing oxidative cell damage (Beckman and 
Ames, 1997, Henle and Linn, 1997). A prominent feature of both abnormal platelet 
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function and dysfunctional endothelium-dependent vasodilation in the setting of 
cardiovascular and thrombotic disease is oxidative stress. Evidence also suggests 
that oxidative stress normally accompanies platelet activation. Platelet aggregation is 
associated with a burst of oxygen consumption (Bressler et al., 1979) and a marked 
rise in glutathione disulfide (Burch and Burch, 1990). While dramatic changes in 
platelet redox status occur during normal aggregation, conditions that provoke 
oxidative stress without inducing a florid aggregation response, have also been 
shown to be prothrombotic. Reactive oxygen species contribute causally to many 
pathophysiologic conditions, and superoxide, in particular, is known to augment 
platelet aggregation responses (Handin et al., 1987). Superoxide and NO readily 
combine to form OONO-, thereby inactivating NO. 
 
Antioxidants may indirectly inhibit platelets through their interference in the 
metabolism of reactive oxygen species, many of which alter platelet function. 
Hydroperoxides produced by activated platelets (prostaglandin G2, 12-hydroperoxy-
eicosatetraenioc acid, and phospholipid hydroperoxides) are metabolized by the 
cytosolic selenium-dependent enzyme cellular glutathione peroxidase. Cellular 
glutathione peroxidase (cGPx) is tightly coupled to the hexose monophosphate shunt 
through reduced nicotinamide adenine dinucleotide phosphate (NADPH), which 
maintains the obligate cosubstrate of cGPx reduced glutathione (GSH) and re-
establishes the platelet thiol redox state via glutathione reductase. Glutathione 
depletion in platelets leads to attenuated cGPx activity and increased lipid 
peroxidation (Calzada et al., 1991). Increased lipid peroxides, in turn, lead to an 
increased likelihood of lipid peroxyl radical formation (LOO), which can react with and 
inactivate NO by forming lipid peroxynitrites (LOONO). Cellular GPx potentiates the 
inhibition of platelet function by NO by reducing both LOOH and derivative LOONOs. 
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1.4.3 Why study Antioxidants? 
In summary, previous studies have clearly shown a role for ROS in the progression of 
vascular disease. Some human antioxidant trials have been promising. However, 
overwhelmingly, clinical trials have failed to show a protective effect of antioxidants in 
humans. A meta-analysis of seven randomized vitamin E trials does not support a 
protective effect of vitamin E supplementation on the progression of cardiovascular 
disease or on clinical events in patients at high risk or with established disease 
(Vivekananthan et al., 2003). The reasons for the failure of these antioxidant trials is 
likely multifactorial. Firstly all of these studies used alpha tocopherol form of vitamin 
E. It is still very difficult to identify the subjects who have an imbalance between ROS 
production and antioxidant defenses and might benefit from antioxidant therapy. 
Furthermore, most patients enrolled in clinical trials have established cardiovascular 
disease, and antioxidant intervention in these cases may be too late to be effective. 
This suggests that antioxidant therapy may be more beneficial as a preventive 
measure rather than a therapeutic tool. The lack of knowledge on the optimal dosage 
for the various antioxidants is also a handicap. More recently, it has become 
apparent that the bioavailability and distribution of administered antioxidants may 
limit their usefulness.  
 
Based on this literature review, there is a need to evaluate the efficacy of several 
classes of antioxidants. Before a potential role for antioxidants in the prevention of 
CVD is elucidated, more carefully designed studies with classic as well as new 
antioxidants in well-defined patient populations, are warranted to provide a definitive 
answer. 
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Studies conducted for this thesis will examine associations between the intake of 
various antioxidants, their effect on prevention of thrombotic risk factors and 
cardiovascular disease 
1.4.4 Aim of the studies undertaken for this thesis 
Atherosclerosis, one of the major causative factors of CVD, is thought to be initiated 
by oxidative stress. Much work has been undertaken to determine the atherogenic 
effects of oxidative damage on platelet activity, lipid profile and glucose uptake by 
skeletal muscle myotubes. Current research shows that dietary antioxidant 
supplementation protects against oxidative stress, and therefore may offer 
preventative measures and treatments for patients with diseases influenced by 
oxidative stress. Cocoa, olive and Gamma tocopherol (vitamin E) are reported to 
have potent antioxidant properties and have been shown to inhibit LDL oxidation in 
vitro. Although there is strong evidence that supports the correlation between 
antioxidant consumption, cholesterol reduction and cardiovascular protection, it 
remains to be elucidated whether theseagents confer benefits through mechanisms 
involving platelet function and glucose uptake. Increased platelet activity and 
impaired lipid profile have been identified to increase the risk factors for 
cardiovascular disease. Therefore, the primary aims of the in vitro and intervention 
studies undertaken for this thesis were to examine if different hydrophilic and lipophilic 
antioxidants could attenuate platelet activity and glucose uptake by skeletal muscle 
myotubes in response to induced oxidative stress.  
 
The aim of the first in vitro study described in Chapter Two was to determine the 
dose-response characteristics of olive leaf extract on platelet activity in healthy 
human subjects. The phenolic compounds of olives leaves used for centuries in the 
Mediterranean diet have been associated with a reduced incidence of heart disease. 
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The active phenolic compounds in olive leaf are known for their capacity to scavenge 
H2O2. 
 
Dietary antioxidant supplements are marketed and used by athletes as a means to 
counteract the oxidative stress of exercise. Whether strenuous exercise does, in fact, 
increase the need for additional antioxidants in the diet is not clear. Therfore, the aim 
of the second study described in Chapter Three was to evaluate effect of exercise, 
training status and cocoa antioxidant on platelet function. The study compared pre 
and post exercise and cocoa supplementation, platelet activity in trained and 
sedentary population.  
 
Results of epidemiological studies demonstrated an inverse relationship between 
vitamin E intake and coronary disease. The activity of vitamin E is derived primarily 
from alpha-tocopherol (α-T) and gamma-tocopherol (γ-T). However, the results of 
clinical trials using α-T are equivocal. 
 
Accordingly, the study described in Chapter Five was undertaken to determine the 
effect of oxidative stress and gamma tocopherol treatment on cultured rat L6 muscle. 
 
In summary, the aim of studies undertaken for this thesis is to provide evidence that 
antioxidant supplementation may be able to improve cardiac health by maintaining 
normal platelet function, controlling lipid levels and improving glucose uptake in 
normal healthy asymptomatic population as well as under induced oxidative stress 
conditions. Results of these studies may be able to demonstrate that various dietary 
sources of antioxidants including foods rich in cocoa, olive and gamma tocopherol 
could be instrumental in combating oxidative stress induced cardiovascular diseases. 
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Chapter Two: The Effects of Polyphenols in Olive Leaves on Platelet Function 
 
Adapted from Nutrition, Metabolism & Cardiovascular Diseases 2008; 18: 127-
132.  
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2.1 Introduction 
Olive leaves and olive oil in the Mediterranean diet have been the focus of many 
epidemiological studies and have been shown to reduce the incidence of heart 
disease (Keys, 1995, Keys, 1970, Cook and Samman, 1996). Adherence to the 
traditional Mediterranean diet is associated with a significant reduction in total 
mortality (Trichopoulou et al., 2003). For example, Estruch et al found that compared 
with a low-fat diet, Mediterranean diet supplemented with olive oil or nuts have 
beneficial effects on cardiovascular risk factors (Estruch et al., 2006). The Lyon Diet 
Heart Study tested a Mediterranean-type diet over long term and suggested that a 
comprehensive strategy to decrease cardiovascular morbidity and mortality should 
include primarily a cardio protective diet (de Lorgeril et al., 1999). 
 
The flavonoid polyphenols in olive are natural antioxidants, which have a host of 
health beneficial effects (Visioli and Galli, 1998). Hydroxytyrosol and tyrosol are 
some of the many phenol compounds in olives that contribute to bitter taste, 
astringency, and resistance to oxidation (Visioli et al., 1998b, Visioli and Galli, 2002, 
McDonald et al., 2001). The active phenolic compounds in the olive leaf extract are 
part of the secoiridoid family, known for their capacity to scavenge H2O2 (Visioli et al., 
1994). Pignatelli et al demonstrated that following stimulation by collagen, there is a 
burst of H2O2 in the process of platelet activation (Pignatelli et al., 1998). H2O2 
activates the enzyme phospholipase C, which brings about arachidonic acid 
metabolism and platelet aggregation.  
 
There is a growing interest in the use of natural antioxidants as bioactive components 
in food, and such foods have been termed “functional foods” (Hertog et al., 1993). 
Due to their ability to scavenge ROS, antioxidants are capable of inhibiting the 
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process of LDL cholesterol oxidation subsequently decreasing the risk of 
cardiovascular diseases (Diaz et al., 1997). Although oxidation of LDL can be 
prevented by the addition of synthetic antioxidants, greater attention is now focused 
on natural antioxidants because of their better safety compared to that of synthetic 
compounds (Amro et al., 2002). The protective effect of these diets, which are rich in 
fruits and vegetables, against coronary heart disease and certain cancers have been 
attributed partly to the antioxidants found in them, particularly to polyphenols (Hertog 
et al., 1993).  
 
In the current study, we used extract of Olea europaea L. leaves to determine the 
effect of olive leaf extract on platelet function in healthy human subjects. 
 
2.2 Methods and Materials 
2.2.1 Subjects 
Following approval by the RMIT University Human Research Ethics Committee, 11 
healthy male volunteers between the ages of 18 to 54 years were recruited for this 
study. All subjects provided written informed consent to undertake the study. 
 
Criteria for subject recruitment for the study included male (since subject numbers 
were small only males were recruited to rule out effect of any menstrual cycle related 
hormonal changes on platelet activity in females), non-smoking, and healthy, with no 
history of cardiovascular disease or diabetes. Subjects were screened via means of a 
questionnaire, which requested information regarding level of physical activity, 
medical history, diet and use of aspirin-type products, non-steroidal anti-inflammatory 
drugs, blood pressure and other drugs. During the testing phase, subjects were 
screened for aspirin intake via platelet aggregation in response to the agonist, 
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Arachidonic Acid. Subjects were requested not to vary their habitual diet for the 
duration of the study. Subjects were required to complete a food diary by food 
frequency questionnaire over a 7-day period to monitor the intake of all foods for an 
estimation of the amount of polyphenol rich food such as omega-3 polyunsaturated 
fatty acid rich foods, alcohol and cocoa products and to confirm study participants 
were not consuming antioxidant supplements. Subjects on medication, antioxidant 
supplements, and who had high dietary intake of alcohol, seafood and cocoa 
products were also excluded from the study. This study did not involve any additional 
dietary supplement intake. 
 
2.2.2 Study design 
A single blinded study involving 11 healthy male volunteers was conducted in the 
Division of Laboratory Medicine, School of Medical Sciences, RMIT University. 
Subjects were overnight fasted before blood collection.  
 
Whole blood, collected on two occasions at weekly interval, was first screened for 
baseline platelet count (PLT) and mean platelet volume (MPV) before second sample 
was analysed with and without the in vitro addition of commercially available olive 
leaf extract (Olive Leaf Australia Pty. Ltd., QLD).  The extract was diluted to produce 
various concentrations, and the amount of platelet aggregation induced at each 
concentration was investigated. The optimal dose was determined from the dose 
response curves.  
2.2.3 Olive leaf extract 
The product Olive Leaf Extract was provided by Olive Leaf Australia Pty. Ltd., QLD. 
Previous composition investigation studies by the company have shown it to be 98% 
pure leaf extract of Olea europaea L. leaves. The product was stated to contain 5.40 
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mg/mL of oleuropein as its active ingredient. The actual product used was dark 
brown fluid, water-extracted olive leaf extract (from fresh Olea europaea leaves) with 
no solvents. The product was aqueous and could therefore be added directly to the 
blood. 
2.2.4 Blood collection 
A total of 12 mL of venous blood per volunteer was collected by a registered nurse at 
RMIT Health Services (Bundoora campus) using a tourniquet and 21-gauge 
Vacuettes© (Greiner bio-one GmbH, Kremsmünster, Austria). Blood was collected 
into 2mL tri-potassium ethylene diamine tetra-acetic acid (EDTA) (1.8 mg/mL), and 4 
mL tri-sodium citrate (3.8%) tubes (Greiner bio-one GmbH, Kremsmünster, Austria). 
The EDTA tube was collected before the tri-sodium citrate tube to avoid the risk of 
collecting platelets activated by venipuncture. Care was taken to ensure minimal 
specimen handling and agitation. 
 
2.2.5 Full blood examination 
EDTA anti-coagulated whole blood was analysed for PLT and MPV parameters using 
the Beckman Coulter Ac.T 5diff analyser (Coulter Corporation, Miami, FL, USA) 
within 15-20 minutes of venipuncture. Prior to full blood examination (FBE) each day, 
the performance of the analyser was validated using Coulter Ac.T 5Diff Control 
Plus, low, normal and high controls (Beckman Coulter, Miami, FL, USA). The 
analyser was also pre-calibrated with the Ac.T 5diff Cal Calibrator (Beckman 
Coulter, Miami, FL, USA). The PLT and MPV parameters of all subjects were 
checked to ensure that they fell within a reference range for healthy adults (150-400 
x 109/L and 6-10 fL respectively). 
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2.2.6 Sample preparation 
Five volume-per-volume (v/v) concentrations of olive leaf extract were added to the 
blood, i.e. 0.1%, 0.3%, 0.5%, 0.7%, and 1.0% (Table 3.1). The concentrations of 
oleuropein from the extract were calculated to be 5.4 µg/mL, 16.2 µg/mL, 27.0 
µg/mL, 37.8 µg/mL, and 54.0 µg/mL respectively. Whole blood without additives 
(containing 0% v/v olive extract or 0 µg/mL oleuropein) was used as a control and 
baseline measurement.  
 
2.2.7 Platelet aggregation 
Whole blood platelet aggregation was measured with an impedance aggregometer 
(Chrono-Log Corp, Philadelphia) equipped with MacLab software (ADInstruments Pty, 
Ltd, Castle Hill, Australia) for data quantitation and analysis. This method has been 
described previously (Murphy et al 2003). Calibrations for impedance and ATP 
release were performed daily before analysing blood samples. 
 
The appropriate volume of olive leaf extract was added to the blood in cuvettes 
(Chrono-Log Corporation, Philadelphia, PA, USA) and incubated at 37°C ± 1.0 for 30 
minutes. Siliconised stir bars (Chrono-Log Corporation, Philadelphia, PA, USA) were 
then added, and the samples were diluted 1:1 with pre-warmed 0.9% (w/v) saline 
(NaCl, BDH AnalaR, MERCK, Pty. Limited, VIC). The samples were then placed 
inside the heating block testing wells of the aggregometer and the respective 
electrodes were immersed into samples for 2 minutes at 37°C ± 1.0 to ensure 
stability before analysis.   
 
 After adding 100 ul chronolume reagent, sample was incubated, and mixed with 
agonists 2 µg collagen/mL [Chrono-Log Corp] [1 mmol arachidonic acid (AA)/L was 
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used to stimulate platelets for repeating the aggregation as a check for anti-
inflammatory intake], and aggregation was recorded for 6 min. ATP release from 
platelets reacted with luciferin-luciferase in the Chrono-Lume reagent and 
luminescence was measured, at 650nM by photomultiplier tube (PMT) built in the 
aggregometer, simultaneously with platelet aggregation. These investigations were 
carried out within 2 hr post venipuncture.  
 
2.2.8 Statistics 
Statistical analyses were performed using Microsoft® Excel 2000 (Microsoft 
Corporation, Redmond, WA, USA) and SPSS® version 12.0 (SPSS Inc., Chicago, IL, 
USA); a significance level of P<0.05 was applied. Analysis of variance (ANOVA) 
adjusted with Sidak simultaneous tests using SPSS® were performed to detect 
significant differences between the concentrations of olive leaf extract tested. Two-
way ANOVA using Microsoft® Excel 2000 was applied to results of ATP release 
curve. 
 
2.3 Results 
2.3.1 Subjects 
Baseline FBE results of 11 subjects showed PLT count of 214 ± 34 x 109/L and MPV 
of 8.0 ± 0.8 fl. All parameters fell within normal reference ranges. All subjects had 
avoided aspirin as normal platelet aggregation curves were obtained using 
arachidonic acid as an agonist. 
 
2.3.2 Whole blood platelet aggregation  
Platelet aggregation, reported as slope (rate of change of impedance in current due 
to clumping of platelets on the electrode), fell in a dose-dependent fashion with a 
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steep fall between 0.7% v/v and 1.0% v/v concentrations of olive leaf extract. Sidak 
95.0% simultaneous confidence intervals found 1.0% v/v (54.0 µg/mL) olive leaf 
extract to be significantly different from baseline (Figure 2.1). 
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Figure 2.1 The effect of increasing concentrations of olive leaf extract on platelet 
aggregation reported as slope-rate of change (Ω/s). Two way ANOVA (Sidak simultaneous 
tests), significantly inhibited platelet aggregation observed at 1.0% v/v olive leaf extract 
(adjusted P=0.0001). Results reported as Mean ± SD 
 
 
2.3.3 ATP release  
ATP release from platelets was similarly antagonised at the optimal dose of 0.7% v/v 
and 1.0% v/v concentrations of olive leaf extract, determined from the earlier dose 
response curves (Figure 2.2). 
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Figure 2.2 Mean concentration of ATP released (nM) at each concentration of olive leaf 
extract (% v/v). Two way ANOVA, significantly inhibited ATP release observed at 1.0% v/v 
olive leaf extract (P<0.02). Results reported as Mean ± SD. 
  * 
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2.4 Discussion 
The findings from this study demonstrate that polyphenols found in olive leaf extract 
are capable of inhibiting in vitro platelet activation in healthy, non-smoking male 
individuals. This finding is in agreement with previous work by Karantonis et al 
reporting that platelet activating factor (PAF) antagonists in olive oil exert significant 
anti-atherosclerotic activity in rabbits (Karantonis et al., 2006). The study by 
Karantonis et al used platelet rich plasma, whereas the current investigation used 
whole blood. Platelet analysis by the whole blood impedance method decreases the 
processing and handling time of the specimen, thereby preserving the integrity of 
platelets, and is therfore a better indicator of platelet activity in situ. 
 
Previous studies by (Visioli et al., 1998a) have demonstrated that oleuropein and 
hydroxytyrosol have capacity to scavenge H2O2 in a dose-dependant fashion. Hence, 
while the mechanism of action whereby these polyphenols are capable of inhibiting 
platelet function is not fully understood. It is hypothesized that this is due to their 
ability to scavenge H2O2 produced during the arachidonic acid metabolism cascade, 
which leads to platelet aggregation (Pignatelli et al., 1998). 
 
This in vitro study has some limitations. It does not take into account several 
variables such as absorption and metabolism of the supplement. There is insufficient 
data in the literature to fully understand the bioavailability of polyphenols such as 
oleuropein, hydroxytyrosol and tyrosol, which are found in olive leaf extract. It is 
known that oleuropein is poorly absorbed due to its large size and planar 
configuration (Edgecombe et al., 2000). It has however been hypothesized that since 
oleuropein is a glycoside, it could probably access a glucose transporter like a 
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sodium-dependent glucose transporter (SGLT1) found on the epithelial cells of the 
small intestine, permitting its entry into the cells. Conversely, Hollman et al. 
postulated that the absorption of the quercetin glycoside, (a similar polyphenolic), 
involved active sugar transporters (Hollman et al., 1995).  
 
Although oleuropein is the only active ingredient found in the olive leaf extract used in 
this study, reports in the literature indicate that oleuropein is not the only phenolic 
compound found in Olea europaea L. leaves. Benavente-García et al. quantified the 
various polyphenols found in Olea europaea L. leaves and reported that oleuropein 
was found to be the largest fraction. Other polyphenols like hydroxytyrosol, caffeic 
acid, luteolin and rutin were also isolated from the leaves (Benavente-Garcia et al., 
2000). The flava-3-nol catechin was also found in olive leaf extract. Data from our 
laboratory demonstrated that catechin is capable of inhibiting platelet function 
because of its antioxidant activity (Murphy et al., 2003). Hydroxytyrosol, caffeic acid, 
luteolin and rutin are also established to have antioxidant activity and H2O2 
scavenging properties (Benavente-Garcia et al., 2002). Polyphenols display a 
synergic behaviour in mixed form, as occurs in olive leaf extract with a high content 
of oleuropein and other active polyphenols (Benavente-Garcia et al., 2002, 
Benavente-Garcia et al., 2000, Benavente-Garcia et al., 1997, Caruso et al., 1999). 
Therefore, the observed platelet inhibition could be attributed to a synergistic effect of 
the various polyphenols, as opposed to oleuropein alone. For this reason, oleuropein 
concentrations were not reported in the dose response curves. The investigations 
involving this particular olive leaf extract can therefore only be considered a primary 
but valuable study. Further work is required for a profile on all the polyphenols found 
in the olive leaf extract.  The results of the present study will need to be validated 
with in vivo evaluation of platelet activation such as urinary thromboxane B2 excretion 
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and evaluation of oxidative stress markers such as isoprostanes (derived from the 
non enzymatic peroxidation of arachidonic acid) to provide insight into the 
mechanisms responsible for the inhibition of platelet function by polyphenols. 
 
In conclusion, we demonstrated that polyphenols from olive leaf extract significantly 
inhibited in vitro platelet aggregation. This has important benefits for the food industry 
as the anti-platelet effects in olive leaves may offer a degree of protection from 
thrombosis and other cardiovascular diseases. Follow up in vivo studies will be 
undertaken to validate the results of current study and to establish the bioavailability 
of these polyphenols. These polyphenols could also be purified and concentrated for 
further studies on platelet aggregation to see their pure effect in vitro and in vivo. 
 
Table 2.1 Volumes of olive leaf extract added to whole blood to achieve v/v concentrations of 
0.1%, 0.3%, 0.5%, 0.7% and 1.0% olive leaf extract concentrations in vitro. 
 
Volume of Olive 
Leaf Extract 
Volume of whole 
blood 
% concentration 
of extract (v/v) 
Concentration of 
Oleuropein 
0 µL 1000 µL 0% (Baseline) 0 µg/mL 
1 µL 999 µL 0.1% 5.4 µg/mL 
3 µL 997 µL 0.3% 16.2 µg/mL 
5 µL 995 µL 0.5% 27.0 µg/mL 
7 µL 993 µL 0.7% 37.8 µg/mL 
10 µL 990 µL 1.0% 54.0 µg/mL 
 
Various concentrations of oleuropein prepared by incubation of olive leaf extract with 
wholw blood were used for platelet aggregation. 
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Chapter Three: The effect of exercise and training status on platelet activation: 
do cocoa polyphenols play a role? 
 
Adapted from Platelets 2006; 17(6): 361–367. 
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3.1 Introduction  
Epidemiological studies have described a complex relation between exercise and 
coronary ischemic syndromes (Powell et al., 1987). Habitual, sustained exercise has 
been postulated to reduce the incidence of ischemic heart disease (Morris et al., 
1953, Morris et al., 1980, Paffenbarger et al., 1984, Kannel et al., 1986, Paffenbarger 
et al., 1986, Fletcher et al., 1992). However, acute exertion has also been reported to 
be a cardiovascular stressor particularly in men who are sedentary (Weaver et al., 
1982, Siscovick et al., 1984b). It has been shown that the hemodynamic 
disturbances and raised shear stress alter the platelet response (Ruggeri, 1994, Kroll 
et al., 1996). Some studies report that exercise de-sensitises the platelets (Wang et 
al., 1994), does not affect the platelets (Drygas, 1988, Sakita et al., 1997, El-Sayed 
et al., 2000), or increases platelet aggregation (Ohri et al., 1983, Ersoz et al., 1997).  
 
We hypothesize that platelets of the subjects who are physically active and those 
who are sedentary may respond differently to same exercise protocol. Exercise 
results in an amplified production of free radicals and other reactive oxygen species 
leading to oxidative stress and cellular damage (Jenkins, 1988). ROS oxidise low-
density lipoproteins, promoting foam cell formation thus accelerating the progression 
of atherosclerosis (Harmut Kuhn, 1997). Excess generation of ROS may overwhelm 
natural cellular antioxidant defences, more so in sedentary than trained men. 
Accordingly, antioxidant supplementation may provide a protective mechanism to 
reduce the harmful effects of ROS (Powers and Hamilton, 1999). We found in our 
previous study that cocoa supplementation modestly reduced platelet aggregation in 
normal healthy subjects (Murphy et al., 2003). 
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The hypothesis of this study was that platelet hyperactivity in response to exercise 
differs between trained and untrained individuals and short-term cocoa polyphenols 
may offer protection by reducing the platelet aggregation.  
  
3.2 Methods and Materials 
Sixteen healthy, age (23 ± 5 yrs), weight (79 ± 11 Kg) and height (184 ± 6 cm) 
matched, male volunteers were recruited for this cross over double blinded study, 
which was approved by the RMIT Human Research Ethics Committee. Twenty 
volunteers were screened of which eighteen met inclusion criteria (two were taking 
dietary supplements regularly). Subsequently, two sedentary subjects withdrew 
because of difficulty performing 1 hour of continuous exercise. 
 
Eight subjects were well trained, as defined by a history of regular (more than 4-
5hrs/wk) participation in aerobic exercise (endurance trained cyclists), higher 
maximum oxygen uptake (VO2max of 59.53 ± 3.59 mL/kg/min) and mean maximal 
power of 235 ± 15W. Eight untrained subjects with lower VO2max of 37.51 ± 3.42 
mL/kg/min and mean maximal power of 161 ± 17W, participated in less than 2 hrs/wk 
of any kind of activity. All subjects were non-smokers with no history of bleeding 
disorders, diseases of the circulatory system or family history of coronary heart 
disease, thrombosis or diabetes. Subjects were requested to inform the investigator if 
they had to take any anti-inflammatory drugs during the study and completed food 
diary to monitor their intake of polyphenol rich food. During intervention subjects 
consumed their habitual diet however, subjects were screened for dietary 
supplements rich in antioxidants such as dietary intake of omega-3 polyunsaturated 
fatty acid rich foods, alcohol, chocolate and cocoa products. Subjects, who were on 
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medication, took dietary supplements, and who had high dietary intakes of alcohol, 
seafood and cocoa and chocolate products were excluded from the study.   
3.2.1 Preliminary testing  
A blood sample (2 mL) was taken and a full blood examination (FBE) was performed 
to check basal total platelet count and mean platelet volume (MPV). Subjects with 
extremely high or low platelet numbers (>400 or <120 x109/L) and high MPV (>10fl) 
were excluded from the study. 
 
All subjects were assessed for VO2max as described by Hawley et al during a 
progressive incremental exercise test on a cycle ergometer (Groningen, The 
Netherlands) (Hawley and Noakes, 1992). The test was undertaken under standard 
laboratory conditions (21–22oC, 40 – 50% room humidity). The maximal test has 
been described in detail previously (Hawley and Noakes, 1992). Briefly, throughout 
the maximal test and during portions of the experimental trials subjects breathed 
through the mouthpiece attached to a Quark b2 metabolic cart (COSMED, Rome, 
Italy). Expired gas was passed through a flow meter, an O2 analyser and a CO2 
analyser that were calibrated prior to testing using a 3 L Hans-Rudolph syringe and 
gases of known concentration (4.00% CO2 and 16.00% O2). The flow meter and gas 
analysers were connected to a computer that calculated minute ventilation (VE), 
oxygen uptake (VO2), carbon dioxide production (VCO2) and respiratory exchange 
ratio (RER) from conventional equation. A maximal test was terminated at the point of 
volitional fatigue which coincided with the inability of a subject to maintain a cadence 
>70 rev.min-1 and/or an RER >1.15. The highest VO2 for any 60 s was taken as the 
subject’s VO2max. Peak sustained power output (PPO) was calculated by adding the 
workload (W) completed on the final (uncompleted) workload to the last successfully 
completed workload. Based on the results of this maximal test and training history, 
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subjects were classified as either “sedentary” (VO2max < 45 mL/kg/min) or “trained” 
(VO2max > 55 mL/kg/min). Subjects with a VO2max of >45 but < 55 mL/kg/min were 
excluded from the study.  
 
3.2.2 Overview of study design  
Following preliminary testing, during the first phase, 8 trained and 8 sedentary 
subjects, as previously determined, were randomly assigned to receive either 
placebo (color and size matched tablets containing <5mg/day cocoa)  or antioxidant 
enriched cocoa polyphenol (236mg/day) supplementsfor 7 days. A one week 
supplementation period was selected to evaluate acute short term supplementation 
effect.  Compliance was excellent as confirmed by exact number of extra tablets 
returned by all subjects. He subject forgot to bring back the remaining tablets, but 
claimed he had some leftover tablets at home. Fasting blood samples were taken pre 
and post 1-hr exercise on 8th day after seven days supplementation. Following a 
further 7-day washout period, subjects were swapped to the other treatment and 
under same protocol; pre and post 1-hr exercise fasting blood samples were 
collected again on 21st day. The content of cocoa polyphenols, defined as flavanols 
and procyanidins in the supplements was determined by HPLC by Mars Technical 
Division, Ballarat, Victoria, Australia.  
 
3.2.3 Experimental trial  
On the morning of an experiment subjects reported to the laboratory between 0700-
0800 hr after a 12-14 hr overnight fast. After a rest period of 10 min, a venous blood 
sample (16 mL) was collected. The subjects then commenced 1 hr of sub maximal 
cycling at 70% of VO2max. Subjects were provided with access to water ad libitum 
throughout the ride. A further blood sample (6 mL) was taken immediately upon 
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completion of the ride, and analysed for total platelet count, hematocrit, mean platelet 
volume (MPV), whole blood platelet aggregation, ATP release from platelet granules, 
and platelet activation by flow cytometry.  
  
3.2.4 Laboratory methods 
3.2.4.1 Blood collection 
 
Venous blood was collected per volunteer using a vacutainer adapter and 21 gauge 
vacuettes  (Greiner bio-one GmbH, Kremsmünster, Austria) at two occasions, both 
pre and post one hour exercise. Blood was collected into 2 mL tri-potassium 
ethylene-diamine-tetra acetic acid EDTA (1.8 mg/mL), 8 mL tri-sodium citrate (3.8%) 
and 10 mL SST (serum separator tubes) tubes (Greiner bio-one GmbH, 
Kremsmünster, Austria). The EDTA tube was used before the tri-sodium citrate tube 
to avoid collecting platelets activated by venipuncture. Care was taken to ensure 
minimal specimen handling and agitation. All blood samples collected were tested 
according to the following protocols. 
 
3.2.4.2 Platelet function tests  
 
Mean platelet volume (MPV) and platelet count were measured by using whole blood 
collected in EDTA-containing tubes on Beckman Coulter Ac.T 5diff analyser 
(Coulter Corporation, Miami, FL, USA). Prior to FBE examination each day the 
performance of the analyser was validated using Coulter Calibrator and Controls 
Plus. Blood collected in citrate-containing tubes was used to determine the extent of 
platelet aggregation and to measure the release of ATP from platelets. Whole blood 
platelet aggregation was measured with an impedance aggregometer (Chrono-Log 
Corp, Philadelphia) equipped with MacLab software (ADInstruments Pty, Ltd, Castle 
Hill, Australia) for data quantitation and analysis. Detailed method has been 
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described previously (Murphy et al., 2003). Calibrations for impedance and ATP 
release were performed daily before analysing blood samples. Briefly citrated whole 
blood was diluted with saline (1:1), 100 uL chronolume reagent was added, sample 
was then incubated, and mixed with agonists 2 µg collagen/mL [Chrono-Log Corp] [1 
mmol arachidonic acid (AA)/L was used to stimulate platelets for repeating the 
aggregation as a check for anti-inflammatory intake], and aggregation was recorded 
for 6 min. ATP release from platelets reacted with luciferin-luciferase in the Chrono-
Lume reagent and luminescence was measured, at 650 nM by photomultiplier tube 
(PMT) built in the aggregometer, simultaneously with platelet aggregation.  
 
Additional aliquots of citrated whole blood were diluted with modified tyrode’s buffer 
and incubated for 5 minutes in the presence of 2 µg collagen/mL. Subsequently, 
aliquots of activated blood were incubated in the dark with monoclonal antibodies, 
phycoerythrin conjugated CD41 (Immunotech, Marseille; which were used to identify 
platelets because it has specificity for the glycoprotein IIb portion of the glycoprotein 
IIb-IIIa antigen present on resting and activated platelets), fluorescein isothiocyanate 
conjugated CD62P (Immunotech; an activation-dependent antibody directed against 
P selectin, a component of the -granule membrane of resting platelets that becomes 
expressed on the platelet surface membrane upon activation), or one of the isotype 
controls, immunoglobulin G1 (IgG1). Samples were fixed with paraformaldehyde and 
incubated to prevent further artifactual in vitro platelet activation. Modified tyrode’s 
buffer was added to terminate the fixation, and samples were analysed on an EPICS 
Elite flow cytometer (Coulter Electronics) equipped with a 15-mW argon laser, with 
excitation at 488 nm. The fluorescence of fluorescein isothiocyanate and 
phycoerythrin was detected by using 525 nM and 575 nM band pass filters, 
respectively. Single platelets were identified by gating on both phycoerythrin positivity 
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(CD41 binding) and characteristic light scatter. Because single platelets are smaller 
and less complex than other blood cells, including aggregated platelets, their forward 
scatter and side scatter are lower in comparison with other cells. Once identified, the 
expression of P-selectin was determined by analysing 20000 free platelets, which 
were collected at a rate between 1300 and 1600 events/s. Activated platelets were 
defined as CD41-positive events that expressed P-selectin. The data are reported as 
a proportion of maximum CD62P expression.  
 
3.2.4.3 Serum Total Antioxidant Status (Olympus: AU2700) 
 
Assay was performed using Randox Total Antioxidant Status kit with lot number 
NX2332. This colorimetric method performs quantitative in vitro determination of total 
antioxidant status in serum or plasma (serum was used in this study). Metmyoglobin 
chromogen with ABTS (2,2-َAzino-di-[3-ethylben 2 thiazoline sulphonate]) incubated 
with substrate H2O2 in presence of antioxidants produces suppressed blue green 
colour measured at 600 nM. Strength of colorimetric wavelength of sample is 
computed against known standard values to give quantitative measure of antioxidant 
status. Analyser was validated by calibrating and running controls provided with the 
Randox kit. 
 
3.2.4.4 Statistical analysis  
Statistical analysis was performed using general linear modal (GLM) with three way 
ANCOVA on Statistical Package for the Social Sciences (SPSS) release 11.5.0, 
copyright@ SPSS Inc.  
 
There were three factors: training (trained vs. sedentary), post treatment exercise 
(pre-exercise vs. post-exercise) and treatment (cocoa vs. placebo). Effect of each 
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factor and combined factors (interaction) on each parameter was analysed. Data is 
reported as mean + SD in Table 1.  
3.3 Results 
3.3.1 Total platelet count  
Trained subjects had significantly higher platelet counts compared with the sedentary 
subjects (235 ± 37 x109/L Vs 208 ± 34 x109/L, p<0.018). Platelet count increased 
significantly (p<0.005) in all subjects after exercise independent of treatment (Figure 
3.1 & Table 3.1). 
 
 
 
 
 
 
 
 
Figure 3.1 Platelet count as mean + SD in sedentary (first two pairs of columns) and trained 
groups (last two pairs of columns) before and after exercise both with and without cocoa 
supplementation. * Significant diference after exercise.  Significant difference between 
trained and sedentary (P<0.05). 
 
3.3.2 CD62p expression (P-selectin) as platelet activation marker  
Trained subjects showed significantly lower (p<0.05) platelet activation compared 
with sedentary both before and after exercise in all subjects, whether on placebo or 
cocoa treatment (Figure 3.2 & Table 3.1). 
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Figure 3.2 Platelet activation as mean + SD in sedentary and trained groups before and after 
exercise both with or without cocoa supplementation.  Significant difference between 
trained and sedentary (P<0.05) 
 
3.3.3 ATP release & Whole blood platelet aggregation 
There was an increase in ATP release from platelets in all subjects after exercise 
(P<0.014). However there was no significant change in aggregation (slope) after 
exercise between either training or treatment groups (Figure 3.3 & Table 3.1).   
 
 
 
 
 
 
Figure 3.3 ATP release from activated platelets as mean + SD in sedentary and trained 
groups before and after exercise both with or without cocoa supplementation. * Significant 
change post exercise (P<0.05) 
 
3.3.4 Mean platelet volume (MPV) and packed cell volume (Hematocrit)  
Mean platelet volume did not change after exercise and was not affected by training 
status.  Hematocrit levels increased in all subjects post exercise but not significantly. 
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3.3.5 Serum total antioxidant status 
The total antioxidant concentration in serum between placebo or cocoa groups after 
one-week supplementation within trained or sedentary did not show any difference. 
Though total antioxidant concentration in trained was generally found to be lower 
than the sedentary however the difference was not significant enough to show any 
effect (Table 3.1). 
 
Table 3.1 Platelet function test results pre and post one-hr exercise in trained and untrained 
healthy men after supplementation with ~240 mg/day cocoa antioxidants.  
 
VARIABLE EXERCISE SEDENTARY (N=8) TRAINED (N=8) 
  Placebo Active Placebo Active 
Platelet Count 
(10ˆ9/L) 
Pre Exercise 211 ± 31 204 ± 37 233 ± 30† 236 ± 35† 
Post Exercise 263 ± 41* 243 ± 47*  271 ± 32 * 273 ± 43*  
CD62p 
(%) 
Pre Exercise 59.3 ± 3.7 57.6 ± 6.1 49.3 ± 6.4† 53.2 ± 6.2† 
Post Exercise 58.4 ± 4.9 55.2 ± 2.6 45.1 ± 7.7† 53.9 ± 5.2† 
ATP Release 
(µm) 
Pre Exercise 1.4 ± 0.7  1.5 ± 0.8  1.4 ± 0.4  1.3 ± 0.6  
Post Exercise 1.8 ± 1.4*  2.0 ± 0.9 *  2.1 ± 1.3 *  2.0 ± 0.6*  
Aggregation/Slope 
(Ω/sec) 
Pre Exercise 0.20 ± 0.05 0.20 ± 0.07 0.20 ± 0.03 0.20 ± 0.02 
Post Exercise 0.21 ± 0.04 0.22 ± 0.05 0.20 ± 0.03  0.20 ± 0.04 
Mean Platelet 
Volume (fl) 
Pre Exercise 7.9 ± 0.7 7.9 ± 0.8 8.0 ± 0.6 8.0 ± 0.7 
Post Exercise 7.9 ± 0.6 8.2 ± 0.6 8.1 ± 0.6 7.9 ± 0.6 
Haematocrit 
(PCV) (%) 
Pre Exercise 47 ± 3 46 ± 4 45 ± 2 45 ± 2 
Post Exercise 49 ± 4 47 ± 4 46 ± 3 46 ± 3 
Total Antioxidant 
Status (mmol/L)‡ 
Pre Exercise 1.34 ± 0.33 1.35 ± 0.22 1.25 ± 0.26 1.24 ± 0.30 
Results reported as Mean ± SD 
* Significantly different from the pre exercise value, P<0.05 
† Significantly different from untrained subjects, P<0.05 
‡ Serum for total antioxidants was collected only before exercise 
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3.4 Discussion  
There is growing interest in the utilization of antioxidant-rich plant extracts as dietary 
food supplements (Packer et al., 1999). However, it has not been clearly established 
if strenuous exercise increases the need for additional antioxidants in the diet. The 
practical significance of this study was that many sedentary people engage in 
occasional strenuous exercise. If the increase in free radicals due to exercise is 
greater than the ability of antioxidants in the body to neutralize them, the radicals will 
attack cellular components like lipids, initiating lipid peroxidation, which may lead to 
platelet hyperactivity and generation of more radicals and ROS that can harm other 
cellular components. This may predispose them to risk of heart disease due to raised 
oxidative stress and platelet activity in response to exercise. 
 
The results of the present study demonstrated that: {1} platelet activation was higher 
in sedentary compared with trained subjects, {2} trained had a higher number of 
platelets compared with sedentary subjects {3} ATP released from platelets (a 
measure of platelet activation via dense granular release from activated platelets) 
was higher after exercise than before in all subjects and {4} platelet count increased 
after 60 min of exercise at a workload of approximately 70% VO2max independent of 
prior training status. However this study did not show that increased platelet activity 
in response to exercise could be normalised with oral supplementation of 236 mg/day 
of cocoa polyphenols given for one week. Previous studies by our group have shown 
that consumption of 236 mg/day for 28 days of cocoa polyphenols, defined as 
flavanols and procyanadins decreased platelet reactivity in healthy subjects (Murphy 
et al., 2003). Other studies with the same cocoa compounds have also shown 
decreased platelet activation and aggregation (ex vivo), but with a higher 
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concentration of 900 mg/d (Rein et al., 2000b, Holt et al., 2002) and decreased 
primary haemostasis 2 hr after consumption of 220 mg/d (Holt et al., 2002). 
 
The results of previous studies have suggested that the risk of primary cardiac arrest 
is transiently increased during vigorous exercise, whereas habitual physical exercise 
is associated with an overall decreased risk of primary cardiac arrest (Siscovick et al., 
1984a, Siscovick et al., 1984b). It has also been shown that platelet response to 
exercise depends on several factors such as the relative intensity of exercise, mode 
of exercise and physical fitness. Mild exercise does not alter and may even suppress 
platelet activation while strenuous exercise causes intensity-dependent platelet 
activation (Wang et al., 1994, Weiss et al., 1998). Our results clearly show that same 
intensity of exercise has different effect on platelet activity in trained and sedentary 
subjects. Sedentary subjects starting the intense exercise show higher platelet 
activation compared to trained subjects under same exercise protocol. 
 
The results of the current investigation demonstrate that even though trained male 
subjects had higher numbers of platelets than untrained males, the platelet activation 
was lower in the trained compared with untrained subjects during aerobic exercise 
undertaken at the same relative intensity. Since trained males exercise on a regular 
basis their platelet count increased accordingly and the overall higher platelet count 
and lower platelet activation in trained men may be due to physiological adaptations 
in response to exercise. It has been shown aerobically fit (high VO2max) compared to 
sedentary man of same age have a natural up regulation in endogenous antioxidant 
defences and more efficient mitochondria functioning (Wilson and Tanaka, 2000, Ji, 
2001). It has been shown that reduced glutathione (GSH) protects against ROS-
induced damage. Moderate to intensive exercise can decrease GSH in trained 
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individuals (Sacheck and Blumberg, 2001). GSH preoxidase is a compensatory 
response to and a sensitive marker of oxidative stress induced by exercise. 
 
An increased rate of oxygen free radical production during exercise may cause 
variations in the platelet reactivity by inducing prostacyclin (PGI2)/ thromboxane 
(TxA2) imbalance and alteration in antioxidant status. Exercise affects platelet 
function by increasing total platelet count (Ohri et al., 1983, Ricci et al., 1991) and 
plasma catecholamines (Ohri et al., 1983, Ikarugi et al., 1997), changing plasma 
lipoprotein profile (Agren et al., 1991, Baumstark et al., 1993), and performance of 
alpha-adrenergic receptors (Goto et al., 1996), impairing sensitivity of platelets to 
PGI2 and nitric oxide (Drygas, 1988, Sakita et al., 1997, Sinzinger and Fitscha, 1986, 
Kishi et al., 1992). Free radicals increase as oxidative phosphorylation and 
catecholamines release increases in response to exercise.  
Chen et al reported that long term training elevated PGI2 level [an inhibitor of 
aggregation] and reduced TxA2 levels [aggregating agent] (Chen et al., 1993). 
Moncada and Vane (1979) suggested that the ratio of PGI2/TxA2 plays an important 
role in determining the extent of platelet aggregation. This could explain why trained 
subjects might be less sensitive to the physiological stimuli compared to sedentary 
subjects when exercising at the same relative intensity. Several other possible 
mechanisms may explain why exercise training reduced the extent of platelet 
activation. First, exercise training may decrease resting plasma catecholamine levels 
(Mazzeo, 1991) and down-regulate the performance of platelet alpha2-adrenergic 
receptors (Lehmann et al., 1986), thus reducing vWF-platelet interaction and platelet 
P-selectin expression. Second, exercise training enhances substantial release of 
nitric oxide from platelet and plasma (Wang et al., 1997, Wang et al., 2000b) as well 
as expression of endothelial nitric oxide synthases (Sessa et al., 1994, Hambrecht et 
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al., 2003). Nitric oxide inhibits the formation of thrombus under high shear flow (Kaul 
et al., 1996) and attenuates agonist-induced up regulation of P-selectin and the 
binding of vWF to platelets.   
Kestin et al also found the platelet activation in trained subjects did not always occur 
after exhaustive exercise, however they did not find difference in baseline results 
between trained and sedentary subjects (Kestin et al., 1993). It is important to 
appreciate effect of exercise is dependent on the duration, intensity, frequency, 
volume and type of exercise, and the training status of subjects participating. These 
factors may be the reason of conflicting baseline results obtained by various studies 
between trained and sedentary subjects. 
The different effects on platelet activation between trained and untrained men in the 
current study may also be partly explained by results of study by Cadroy et al in 
which it was suggested that strenuous exercise increases thrombin generation from 
the vessel wall in sedentary (untrained) subjects which acts as a trigger for platelet 
activation (Cadroy et al., 2002).  
 
We found raised ATP release, without an increase in platelet aggregation post 
exercise in this study. This discrepancy between collagen-induced platelet 
aggregation and release may be because of the possibility that the signalling 
pathways in response to exercise do not have similar sensitivities. Ficicilar et al also 
demonstrated similar findings (Ficicilar et al., 2003). 
 
There was an increase in hematocrit (packed cell volume) levels post exercise in all 
the subjects however the increase was not significant enough to shift plasma volume 
to the extent of dehydration that would affect the platelet function.  
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This study aimed to determine whether one week supplementation of cocoa 
polyphenols provided any protection by preventing platelet activation following 
exercise in trained or sedentary subjects. The dose of cocoa supplement (~240 
mg/day) given to the subjects in this study was based on the previous studies 
conducted on normal subjects, where a significant decrease was observed in 
aggregation of platelets stimulated with agonists ADP and collagen (p-value <0.02) 
after four weeks of supplementation (Murphy et al., 2003). However, in the current 
study, no significant change was found in the total antioxidant levels in serum and 
therefore no effect on platelet activation was found post exercise as a result of oral 
consumption of cocoa antioxidants over a week. A dose sufficient to decrease 
platelet activity of resting platelets may not be enough to decrease hyperactivity of 
platelets in response to exercise. Further studies need to be conducted over a longer 
period of time and using a dose-response study to determine if it is possible 
counteract exercise effect using cocoa polyphenols.  
 
In conclusion, the results from the present study demonstrate that exercise does 
increase the total platelet count and the amount of ATP released from the platelets. 
There is an inverse relationship between platelet numbers and activation status 
between trained and sedentary, suggesting that for optimal platelet function, 
moderate regular training is better than the sudden exhaustive exercise by the 
sedentary men. Oxidative stress due to increased O2 uptake during exercise does 
play a role in platelet activation; however short-term antioxidants (cocoa polyphenol) 
supplementation did not provide the protection in this study. Future investigations 
should determine the optimal dose and duration of the time required for cocoa 
polyphenols to beneficially effect platelet function following exercise.  
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Chapter Four: Effects of Gamma-Tocopherol Supplementation on Thrombotic 
Risk Factors 
 
Adapted from Asia Pacific J Clin Nutr 2007; 16 (3):422-428 
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4.1 Introduction 
Vitamin E is an essential nutrient, the main lipid soluble antioxidant, and plays a 
significant role in protecting biological membranes and lipoproteins from oxidative 
damage caused by free radicals (Esterbauer et al., 1991, Patel et al., 1991, Brigelius-
Flohe and Traber, 1999). Vitamin E is not a single compound with at least four 
tocopherols (α, β, δ and γ-tocopherol) and four tocotrienols (α, β, δ and γ-tocotrienol) 
known (Regina et al., 2002). The antioxidant activity of vitamin E is derived primarily 
from α-tocopherol and γ-tocopherol, of which α-tocopherol is most biologically active 
and the predominant form found in blood. In contrast, the predominant form of 
vitamin E found in food is γ–tocopherol (Wagner et al., 2004). The dietary intake of γ-
tocopherol is at least two times that of α-tocopherol in Western diets, while the 
concentrations of α-tocopherol in human blood are generally four times higher than 
those of γ-tocopherol (Wagner et al., 2004). 
 
An inverse relationship has been found between acute coronary events and 
antioxidant vitamin E intake. For example, epidemiological studies have shown that 
vitamin E (α-tocopherol and γ-tocopherol) is associated with reduced number of 
ischemic cardiac events in patients with documented coronary artery disease (Gey et 
al., 1991). Tocotrienols have also been shown to be beneficial by attenuating the 
formation of atherosclerotic lesions and decreasing serum cholesterol effects in 
animal and in vitro studies but results in humans have been inconclusive (Hosomi et 
al., 1997, Black et al., 2000, Mustad et al., 2002). The results of large clinical trials 
examining effect of Vitamin E (tocopherols as well as tocotrienols) on cardiovascular 
diseases have been equivocal (Devaraj and Traber, 2003). Supplementation with 
large amounts of α-tocopherol (1,200 IU per day) has been shown to decrease blood 
concentrations of γ-tocopherol (Handelman et al., 1985). Gamma tocopherol has 
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been found to be more effective than α-tocopherol in protecting against certain 
specific types of oxidative damage.  
 
Saldeen et al showed an antithrombotic effect of vitamin E (γ-tocopherol and α-
tocopherol) on thrombus formation, with more pronounced effect with gamma-
tocopherol (Saldeen et al., 1999, Liu et al., 2003). These workers also demonstrated 
that platelet aggregation was inhibited more potently with a mixed tocopherol 
preparation (100 mg γ-tocopherol, 40 mg δ-tocopherol, and 20 mg α-tocopherol) than 
with α-tocopherol alone and attributed this observation to increased NO release, 
endothelial constitutive nitric-oxide synthase (ecNOS) activation, and superoxide 
dismutase protein content in platelets in response to mixed tocopherol (Saldeen et 
al., 1999). 
 
In a placebo controlled double-blind study, we determined the effect of 5 wk of 
supplementation with γ-tocopherol at different doses (100 mg/d or 200 mg/d) on 
thrombotic risk factors, including platelet aggregation and activation. The effect of 
supplementation on plasma lipids and inflammation marker CRP was also 
investigated. 
 
4.2 Methods and Materials 
4.2.1 Subjects and dietary intake 
After obtaining approval from RMIT Human Research Ethics Committee, 42 healthy 
volunteers were recruited by newspaper advertising and then randomly assigned to 
one of the three groups. Sample size and supplementation period was based on a 
similar study (Liu et al., 2003). All the subjects were between 20 to 40 years old with 
no known medical history. None were on any form of medication for the duration of 
  87
the study. Exclusion criteria included heavy drinking, smoking, and taking anti-
inflammatory medication and antioxidant supplements or antioxidant rich food 
interfering with platelet function in the 2 wk prior to study entry. None of the subjects 
had a history of bleeding disorders, diseases of the circulatory system or diabetes. 
Two subjects withdrew from the study due to time constraints while one subject was 
withdrawn due to difficulty in phlebotomy. No subjects used any platelet inhibitors 
during study.  
  
Dietary γ-tocopherol supplementation was achieved through consumption of tablets 
after signed informed consent was obtained from all participants. Fourteen healthy 
subjects (7 male and 7 female) consumed 100 mg/day of γ-tocopherol and 13 (7 
male and 6 female) consumed 200 mg/d of γ-tocopherol while 12 (5 male and 7 
female) received colour and flavour-matched placebo (soybean capsules with less 
than 5 mg/d γ-tocopherol) for 5 wks.  Tama Biochemical Company Ltd Japan 
supplied all γ-tocopherol and placebo capsules. 
 
Subjects were required to complete a food frequency questionnaire over a 7-day 
period before commencing dietary supplementation, to confirm they were not 
consuming antioxidant rich foods or antioxidant supplements. If voluteers were on 
antioxidant supplements or were regularly taking food very rich in antioxidants were 
not included to participate in the study. Baseline alpha and gammatocopherol levels 
were analysed to confirm that concentrations of serum tocopherols were not 
significantly different between subjects. 
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Fasting blood samples were collected for baseline assessment prior to the study and 
after 5 wks of supplementation. All the procedures were followed in accordance with 
RMIT HREC guidelines. 
 
4.2.2 Experimental Trial 
On the morning of an experiment subjects reported to the laboratory between 0700-
0800 h after a 12-14 h overnight fast. A resting blood sample was obtained for total 
platelet count, whole blood platelet aggregation, ATP release from platelet granules, 
mean platelet volume (MPV), flow cytometry for platelet activation marker, total 
cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) 
cholesterol and triacylglycerols. CRP and serum α- & γ-tocopherol concentrations 
were also evaluated.  
  
4.2.3 Laboratory methods 
4.2.3.1 Blood collection 
A total of 20 mL of venous blood was collected using a vacutainer adapter and 21 
gauge vacuettes (Greiner bio-one GmbH, Kremsmünster, Austria) on two occasions. 
Blood was collected into 2 mL tri-potassium ethylene-diamine-tetra acetic acid EDTA 
(1.8 mg/mL), 8 mL tri-sodium citrate (3.8%) and 10 mL SST (serum separator tubes) 
tubes (Greiner bio-one GmbH, Kremsmünster, Austria). The EDTA tube was 
collected before the tri-sodium citrate tube to avoid collecting platelets activated by 
venipuncture. Care was taken to ensure minimal specimen handling and agitation. All 
blood samples collected were tested according to the protocols described 
subsequently. 
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4.2.3.2 Platelet function tests 
Platelet count and MPV were measured by using whole blood collected in EDTA-
containing tubes with the use of a Beckman Coulter Ac.T 5diff CP analyser (Coulter 
Corporation, Miami, FL, USA). Performance of the analyser was validated using 
Coulter Calibrator and Controls Plus.  
 
Whole blood platelet aggregation was measured with an impedance aggregometer 
(Chrono-Log Corp, Philadelphia) equipped with MacLab software (ADInstruments Pty, 
Ltd, Castle Hill, Australia) for data quantitation and analysis. This method has been 
described previously (Murphy et al., 2003). Calibrations for impedance and ATP 
release were performed daily before analysing blood samples. Briefly citrated whole 
blood was diluted with saline (1:1), 100 uL chronolume reagent was added, sample 
was then incubated, and mixed with agonists 2 µg collagen/mL [Chrono-Log Corp] [1 
mmol arachidonic acid (AA)/L was used to stimulate platelets for repeating the 
aggregation as a check for anti-inflammatory intake], and aggregation was recorded 
for 6 min.  ATP released from activated platelets reacted with luciferin-luciferase in 
the Chrono-Lume reagent added to diluted blood sample. This reaction increased 
luminescence, which was measured, at 650 nM by photomultiplier tube (PMT) built in 
the aggregometer.  
 
 Additional aliquots of citrated whole blood diluted in modified tyrode’s buffer were 
activated with 2 µg/mL collagen, and then incubated in the dark with monoclonal 
antibodies, phycoerythrin conjugated CD41 (Immunotech, Marseille; which were used 
to identify platelets because it has specificity for the glycoprotein IIb portion of the 
glycoprotein IIb-IIIa antigen present on resting and activated platelets), fluorescein 
isothiocyanate conjugated CD62p (Immunotech; an activation-dependent antibody 
directed against P-selectin, a component of the -granule membrane of resting 
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platelets that becomes expressed on the platelet surface membrane upon activation), 
or one of the isotype controls, immunoglobulin G1 (IgG1). Samples were fixed with 
paraformaldehyde to prevent artifactual in vitro platelet activation. Modified tyrode’s 
buffer terminated the fixation, and samples were analysed on an EPICS Elite flow 
cytometer (Coulter Electronics) equipped with a 15-mW argon laser, at an excitation 
of 488 nm. The fluorescence of fluorescein isothiocyanate and phycoerythrin was 
detected by using 525 nm and 575 nm band pass filters respectively. Activated 
platelets were defined as CD41-positive events that expressed P-selectin. The data 
are reported as a proportion of maximum CD62P expression.  
 
4.2.3.3 Lipid Screening and CRP Analysis 
Lipids and CRP were analysed on the automated Olympus AU2700 biochemical 
analyser. The instrument was validated by calibrating and running controls for each 
parameter. Enzymatic colorimetric methods were used for measuring total cholesterol 
(based on cholesterol oxidase method), HDL cholesterol (determined using anti 
human-beta-lipoprotein antibody binding to lipoproteins other than HDL) and 
triacylglycerols (based on a method with glycerol blank). 
 
 LDL cholesterol was calculated, using following Friedwald formula (Friedwald et al., 
1972): LDL Cholesterol = Total cholesterol – [HDL Cholesterol + VLDL], Where, 
VLDL = triacylglycerols/5 
 
CRP was measured using immuno-turbidimetric method using anti-human CRP 
antibodies to form insoluble aggregates.  
 
4.2.3.4 Serum Αlpha and Gamma-tocopherol Concentration 
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The Shimadzu HPLC system (Kyoto, Japan) used in this study consisted of a 
chromatograph LC-10AD and spectrofluorophotometer detector (RF-551) equipped 
with a 12 µl LC flow cell. γ-tocopherol, dl-α-tocopherol and dl-α-tocopheryl acetate 
were detected at excitation λ=298 nm, emission λ=325 nm, recorded by a CR6A 
Chromatopac Recorded /Integrator. 
 
For the analysis a reversed-phase C-18 column, with a mobile phase of Acetonitrile: 
Dichloromethane: Methanol (7:2:1), at a flow rate of 1.0 mL/min was employed. 
Quantitation of these compounds was achieved using linear calibration curves 
constructed from the peak area versus the concentration of the standard compound.  
Before starting a sample run, external standards, followed by an internal QC (plasma 
frozen and allocated into multiple vials on day one from a normal subject) were 
checked.  
 
4.2.3.5 Statistical analysis 
 
Data are presented as means ± SDs. The data analyses were performed using a 
SPSS version 11.5 program (SPSS Corporation, Chicago IL, USA). Effects of 
different Vitamin E (γ-tocopherol) doses (dose effect) on the parameters were 
analysed using GLM repeated measures of ANOVA adjusted for baseline values. 
Changes between pre and post treatment in same dose (treatment effect) were 
assessed using paired t-test. p values <0.05 were considered significant.  
 
4.3 Results 
Compliance was good, as assessed by the number of pills returned and measure of 
serum α and γ-tocopherol concentrations. All the subjects returned all of the extra 
tablets (three extra doses were given to all subjects on placebo and 100mg/day γ-
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tocopherol and two extra doses was given to subjects on 200mg/day γ-tocopherol). 
Two subjects on placebo and one subject on 100mg/day γ-tocopherol missed one or 
two doses as they returned more tablets than expected. No side effects from the 
active or placebo tablets were reported.  
 
Baseline results for all groups were comparable. Five week of supplementation with 
100 mg and 200 mg γ-tocopherol resulted in increased concentrations of serum γ-
tocopherol (p<0.05). The serum level of α-tocopherol did not change after 
intervention in any group (Table 4.1). 
 
There was a significant effect of γ-tocopherol treatment on platelet activation: p-
selectin (CD62p%) decreased significantly after both doses (p<0.05), with little 
change after placebo (Table 4.2). 
 
MPV decreased significantly with 100 mg γ-tocopherol treatment (p<0.05) but the 
decrease was not statistically significant for the higher dose. Platelet aggregation 
also decreased significantly with 100 mg γ-tocopherol (p<0.05) though little effect 
was seen with 200 mg γ-tocopherol or placebo (Table 4.2). 
 
Gamma-tocopherol treatment resulted in a significant effect on LDL cholesterol. LDL 
cholesterol was significantly decreased following 100 mg/d of γ-tocopherol 
supplementation (p<0.05) (Table 4.3).  
 
HDL cholesterol increased significantly with 100 mg γ-tocopherol and placebo. 
However a similar increase was not found with 200 mg γ-tocopherol suggesting the 
increase is random and unlikely due to γ-tocopherol treatment (Table 4.3). 
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Inflammation marker CRP also decreased though not significantly after 
supplementation with 200 mg γ-tocopherol. There were no significant changes in the 
serum levels of triacylglycerol, or in the whole blood platelet count and ATP release. 
 
4.4 Discussion 
The potentially beneficial effects of vitamin E on cardiovascular disease have been 
intensively investigated in many interventional and epidemiological studies. However, 
most of these studies focused exclusively on α-tocopherol and the protective effects 
of α-tocopherol supplementation on CVD is equivocal (Jha et al., 1995, Marchioli, 
1999). Accordingly, we evaluated the effect of pure γ-tocopherol on platelet function, 
lipid concentrations and inflammation marker in blood. To the best of our knowledge, 
this is the first study that provides in vivo relationship between pure γ-tocopherol and 
thrombotic risk factors. 
 
Specifically, the present study determined the effect of two doses of γ-tocopherol on 
platelet function, lipid profile and inflammation marker CRP in human subjects. We 
observed a significant increase in serum γ-tocopherol concentrations after both 
doses. A significant decrease in platelet activity post 200 mg and 100 mg γ-
tocopherol dose was also observed, though the changes between groups were not 
statistically significant. There was also a significant reduction in MPV, platelet 
aggregation and LDL cholesterol post 100 mg γ-tocopherol supplementation only.  
 
Serum γ-tocopherol concentrations increased significantly in all subjects in 
accordance with the concentration of dose, while no change was observed in serum 
α-tocopherol concentrations. This suggests that any changes observed in this study 
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in the platelet function and lipid profile would have been due to γ-tocopherol 
ingestion. 
 
Several independent investigations have demonstrated that the blood concentration 
of γ-tocopherol, not α-tocopherol, was negatively correlated to the incidence of 
coronary heart disease (Kontush et al., 1999, Ohrvall et al., 1996). Supplementation 
with large amounts of α-tocopherol was shown to increase the breakdown and 
decrease blood concentrations of γ-tocopherol, (Morinobu et al., 2003, Handelman et 
al., 1985) as a result of the function of the hepatic α-tocopherol transfer protein (α-
TTP), which preferentially incorporates α-tocopherol into the plasma (Devaraj and 
Traber, 2003). Hosomi found that the biological activity of vitamin E analogs 
correlates to their affinity for α-TTP (Hosomi et al., 1997). Chopra and Bhagavan 
showed that bioavailability of both natural and synthetic α-tocopherol significantly 
suppresses the serum γ-tocopherol to the same extent (Chopra and Bhagavan, 
1999). 
 
Our results could explain the findings of previous epidemiological studies showing 
inverse correlation between vitamin E intake and incidence of CVD. It has been 
shown dietary source of vitamin E is much higher in γ-tocopherol (Wagner et al., 
2004) compared to α-tocopherol, but all the investigational studies used very high 
concentration of α-tocopherol, which could have broken down the γ-tocopherol 
(Handelman et al., 1985) and nullified the effect of vitamin E seen by previous 
studies. High dose of α-tocopherol reduces intestinal absorption, cell membrane 
transport and utilisation of other forms of vitamin E, especially γ-tocopherol 
(Handelman et al., 1994, Handelman et al., 1985, Friedrich, 2004). The hepatic α-
TTP has the greatest affinity for α-tocopherol compared to γ-tocopherol and is crucial 
for the relative percentage of transport of the various forms of vitamin E in the plasma 
  95
lipoproteins (Friedrich, 2004, Hosomi et al., 1997, Wagner et al., 2004). This 
imbalance of α-tocopherol / γ-tocopherol levels in plasma may have significant health 
consequences (Ohrvall et al., 1996, Hosomi et al., 1997). 
 
Liu et al have shown in various animal and human studies that mixed tocopherols are 
more potent in preventing platelet aggregation and have stronger inhibitory effect on 
lipid per oxidation than α-tocopherol alone (Liu et al., 2002, Liu et al., 2003, Li et al., 
1999, Saldeen et al., 1999). We further narrowed down the mix tocopherol to γ-
tocopherol as it is a rich source of dietary antioxidant.  In the current study we used a 
pure form of γ-tocopherol and our results suggest that γ-tocopherol supplementation 
had a direct positive effect on platelet activity and LDL cholesterol concentrations in 
blood of normal healthy people. 
 
Circulating activated platelets are useful markers of local thrombotic events occurring 
in cardiovascular diseases. We used flow cytometry to detect circulating activated 
platelets through expression of platelet surface glycoprotein, p-selectin, also known 
as CD62p. The p-selectin, is rapidly translocated from α-granules inside the platelets 
to the cell surface on stimulation by physiological agonists. During agonist-induced 
platelet activation, energy-dependent fusion of both alpha and dense granules with 
the plasma membrane permits expression of p-selectin, which promote and 
propagate platelet adhesion to endothelial cells, neutrophils and monocytes (Hsu-Lin 
et al., 1984). 
 
One possible mechanism by which γ-tocopherol might have reduced platelet activity 
(i.e. the reduced expression of p-selectin through decreased CD62p binding on 
platelet surface) could be related to platelet derived NO bioactivity. Impaired platelet 
NO production and decreased bioavailability of NO have been associated with 
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coronary disease states (Freedman et al., 1998). Platelet-derived NO has been found 
to inhibit platelet aggregation and reduce platelet recruitment to a growing thrombus 
(Williams and Nollert, 2004). α-tocopherol might increase platelet NO release by its 
free radical scavenging activity and by preventing it’s quenching by peroxyl radicals ( 
Huie and Padmaja, 1993, Freedman et al., 2000). One compensatory mechanism is 
nitration of γ-tocopherol, through available nitration-prone positions on the chromanol 
ring of γ-tocopherol (Christen et al., 1997, Rubbo et al., 1994) and thus depleting NO 
by reacting with it, which leads to an up-regulation of NO synthesis (Williams and 
Nollert, 2004). Nitration of gamma tocopherol uses up nitric oxide and thus by 
feedback mechanism NO synthesis might be upregulated.  Freedman suggested α-
tocopherol might also be responsible in balancing NO and SOD in human platelets 
(Freedman et al., 2000). Saldeen et al suggested up-regulation of SOD by both α-
tocopherol and γ-tocopherol might be important mechanism for the effect of γ-
tocopherol on platelet aggregation, but they found γ-tocopherol to be more potent 
than α-tocopherol in these effects (Saldeen et al., 1999). 
 
A decrease in platelet activation could possibly be explained in terms of antioxidant 
effect of γ-tocopherol. Jiang et al demonstrated cyclooxygenase-2 (COX-2) catalyses 
the synthesis of prostaglandins through oxidation of arachidonic acid, which are 
important elements within the inflammatory process as well as platelet activation. 
They found COX-2 activity is inhibited by γ-tocopherol but not by α-tocopherol (Jiang 
and Ames, 2003, Jiang et al., 2001, Jiang et al., 2000). 
 
Significant decrease in LDL cholesterol is indicative of improved lipid profile, which 
may also explain the reduced platelet activity observed in this study. In recent in vitro 
studies, γ-tocopherol has been shown to inhibit lipid per oxidative damage (Wolf, 
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1997) and to trap mutagenic electrophiles (Christen et al., 1997) more efficiently than 
α-tocopherol. This finding supports our results demonstrating an improved lipid profile 
and a trend of reduction in platelet activity post γ-tocopherol supplementation. Since  
LDL cholesterol is decreased therefore concentration of oxidised LDL should also be 
low, thus reducing risk of foam cell formation and hence risk of thrombosis. 
 
Contrary to our findings, Jiang and Ames also provided strong evidence that γ-
tocopherol shows anti-inflammatory activity in vivo in rats (Jiang and Ames, 2003). 
One of the reasons for that could be that most of baseline results in our study were 
normal, around 2 mg/L and so there was not much scope for the values to further go 
down. It will be more realistic in future to evaluate the effect of γ-tocopherol on 
populations with higher inflammatory conditions. 
 
In conclusion, the results from the current study suggest that the daily consumption 
of small amounts of γ-tocopherol, in conjunction with usual dietary intake from mixed 
food sources may provide protection from oxidative damage and prevent thrombosis. 
Further cellular research would be valuable in helping to understand the mechanisms 
behind the biological effects of γ-tocopherol in higher risk populations such as 
diabetic subjects or those with known cardiovascular disease. Potential synergistic 
effects between γ-tocopherol and other antioxidants and comparison with α-
tocopherol supplementation could also be explored to clarify the role of γ-tocopherol 
in human health. 
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Chapter Five: Oxidative stress-induced insulin resistance in skeletal muscle 
cells is ameliorated by gamma-tocopherol treatment. 
Manuscript accepted for publication by European Journal of Nutrition on 09 Sep 2008 
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5.1 Introduction 
There is accumulating evidence that the generation of reactive oxygen species leads 
to increased oxidative stress in a number of insulin sensitive tissues resulting in a 
variety of conditions including type 2 diabetes and cardiovascular disease (West, 
2000) . Antioxidant agents have been proposed to arrest some of the deleterious 
effects of ROS (Chan, 1998) either by donating hydrogen to free radicals or by 
accepting free radicals  and therefore neutralising their effect. Gamma tocopherol, an 
isoform of Vitamin E present in food, has been shown to have potent antioxidant 
effects (Wolf, 1997). It has been shown to inhibit platelet aggregation more potently in 
platelets isolated from humans supplemented with a mixed tocopherol preparation 
than in platelets isolated from humans supplemented with alpha-tocopherol alone (Liu 
et al., 2003). In addition, we have previously demonstrated that pure gamma 
tocopherol inhibited platelet aggregation and improved lipid profile in normal healthy 
subjects, thereby playing a role in prevention of thrombosis (Singh et al., 2007).  
 
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in various 
tissues and in particular, skeletal muscle, the primary site for insulin-stimulated 
glucose disposal (DeFronzo et al., 1985 ) . While there is evidence that oxidative 
stress leads to insulin resistance (Evans et al., 2003), tissue damage and 
pathogenesis of late diabetic complications (Rosen et al., 2001), the mechanisms 
responsible remain unclear. In skeletal muscle cells, uptake of glucose depends on 
the insulin stimulated translocation of the glucose transporter GLUT4  to cell surface 
(Houseknecht and Kahn, 1997). Signalling to GLUT4 in skeletal muscle requires 
tyrosine phosphorylation of insulin receptor substrate (IRS)-1, which recruits and 
activates phosphatidylinositol (PI) 3-kinase (Thirone et al., 2006).  
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Recently an Akt substrate with molecular weight of 160 kDa (AS160) and a molecular 
signature of a Rab-GAP has been identified as an important regulator of GLUT4 
traffic (Kane et al., 2002). Rab-GAP domains modulate the activity of Rab proteins, 
which are involved in the regulation of several membrane transport steps, including 
vesicle budding, motility, tethering and fusion (Zerial and McBride, 2001). Insulin 
stimulation of skeletal muscle leads to phosphorylation of AS160, a process 
dependent on Akt (Bruss et al., 2005, Bouzakri et al., 2006). Impairments in insulin 
action on AS160 accompany defects in glucose transport in humans. In skeletal 
muscle from Akt2 knock-out mice, insulin-mediated AS160 phosphorylation and 
glucose uptake are severely blunted, which highlights an absolute requirement of Akt 
for insulin-mediated action to AS160 (Kramer et al., 2006). 
 
The effects of ROS on insulin signalling cascade are equivocal (Hayes and 
Lockwood, 1987, Heffetz et al., 1990, Hansen et al., 1999, Rudich et al., 1997), but 
the results of many studies demonstrate that ROS impairs insulin mediated glucose 
uptake (Hansen et al., 1999, Rudich et al., 1998, West, 2000).  While it has been 
proposed that vitamin E supplementation might prevent ROS-induced impairment of 
insulin signalling (Faure et al., 1997), studies of the effects of antioxidant treatment 
on insulin signalling and functional measures of glucose transport are lacking. If ROS 
are involved in causing damage to cellular signalling machinery, antioxidant 
treatment may be able to alleviate or abolish that outcome. Accordingly, the primary 
purpose of the current investigation was to determine whether gamma tocopherol, 
which we have recently demonstrated to have potent antioxidant properties (Singh et 
al., 2007), could ameliorate the deleterious effects of oxidative stress on insulin 
sensitivity. To the best of our knowledge, this is the first study to investigate effect of 
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gamma tocopherol on glucose uptake and the most distal signalling protein involved 
in GLUT4 translocation, AS160. 
 
5.2 Methods and Materials 
5.2.1 Cell culture 
L6 skeletal myoblasts (American Type Cell Collection) were cultured following aseptic 
techniques in 75cm² flasks containing growth media, which consisted of DMEM 
supplemented with 10% FBS, 1% penicillin/streptomycin (v:v) at 37°C in 5% 
CO2/95%O2 in humidified air. Media was replaced daily with pre-warmed media 
(37ºC) until the cells were 60–70% confluent. Cells were washed twice with pre-
warmed PBS then detached with 2 ml of 0.25% trypsin for 3-4 min with intermittent 
shaking. Once the cells were completely detached the total number of cells were 
counted then seeded into six well plates at 7000 cells per cm². Cells were grown to 
about 70% confluency in α modified essential medium (αMEM) +10% FBS before 
changing to differentiation media (αMEM +2% FBS) to allow myoblasts to 
differentiate into myotubes. 
 
Experimental treatments were conducted after two days, by which time nearly all of 
the myoblasts had fused to form myotubes. Cells were incubated with Gamma 
tocopherol for 24 hr (with concentrations indicated) and oxidative stress was 
introduced by incubation with 100mU/mL glucose oxidase for 1 hr. 
 
5.2.2 Deoxyglucose uptake 
For determination of 2-deoxy-D-[3H]-glucose uptake, myotubes were incubated in 
αMEM without glucose with 0.1% FBS for 4 hr. Cells were washed twice with warm 
PBS (containing 0.1% FBS) and equilibrated in 2mL no Glucose-α-MEM for 30 min 
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followed by incubation with 100 nM insulin for 30 min or without (basal), before 800 
µL of radioactive media (1 µCi/mL 2-deoxy-D(3-H)glucose,10 µM 2-deoxy-D-glucose 
in α-MEM, 0.1%FBS) was added to each well. After 30 min media was aspirated and 
the assay stopped by washing cells twice in ice-cold PBS. Cells were then lysed in 1 
mL of 0.3M NaOH and 800 µL of the lysate in 4 mL of scintillation fluid was counted 
via liquid scintillation. 
 
5.2.3 Determination of protein content in L6 myotubes by Western blotting 
 
L6 myotubes were grown, differentiated and treated as described under cell culture 
above.  Lysis buffer (20 mM HEPES (pH 7.4), 2mM EDTA, 50mM NaF, 5 mM 
Na4P2O7, 1% NP40 and phosphatase and protease inhibitor cocktails) was added 
and cells rapidly scraped then transferred to a 1.5ml tube and rapidly frozen in liquid 
nitrogen for later analysis. Subsequently, cell culture lysates were spun at 16,000 g 
for 5 minutes, then 5µl of the supernatant taken and diluted 1:25 with water, before 
the protein concentration was determined using a commercially available kit (BCATM 
Protein Assay Kit, Pierce, USA) using absorbance spectrophotometry. Absorbance of 
standards and samples was determined at 560 nm on a spectrophotometer (Victor3 
TM 1420, Multilabel Counter, Wallac) and the protein content calculated from the 
linear regression.  
 
Proteins were then solubilised in Lamelli’s buffer (4x pH 6.8 consisting of 40% 
glycerol, 8.2%SDS (Sodium Dodecyl Sulphate), 0.5 M Tris-HCl, 40mM dithiotrietol 
plus bromophenol blue) was added to 40 µg of sample heated for 5 min at 85°C, and 
proteins resolved by SDS-PAGE using pre-cast polyacrylamide gradient gels and 
commercially available electrophoresis reagents (Invitrogen, Australia). A molecular 
weight protein standard (Precision plus Protein Standards, Biorad), and solubilised 
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protein samples were loaded into individual wells. The gel was run at 150 V until 
proteins had sufficiently migrated through the gel. 
 
Separated proteins were then transferred to a PVDF membrane using pre-developed 
reagents and standard transfer sandwich apparatus (Invitrogen, Victoria, Australia). 
Proteins were transferred at a constant voltage of 20 V for 100 (Akt) or 180 (AS160) 
min. After the transfer, the membrane was washed with Tris buffered saline with 
Tween (TBST; 20 mM Tris, 140 mM Nacl, 0.05% Tween 20, pH 7.6). The membrane 
was blocked with 5% skim milk powder (w/v) in TBST on a rocker at room 
temperature for 1 h. After blocking, membranes were washed with TBST and 
incubated with primary antibodies (diluted 1:1000 in TBST+1%BSA) specific for 
phospho-Akt-Ser473, β-actin and Phospho-Akt-Substrate (Cell Signalling 
Technology), overnight on a rocker at 40C. Membranes were washed three times with 
TBST then incubated with secondary antibody (1:5000 anti-rabbit antibodies in 
TBST) for 1 h at room temperature. The membrane was then washed (6x10 min) with 
TBST and immunoreactive bands detected with 2 ml of chemiluminescence reagent 
(ECLTM Western Blotting Detection Reagents, Amersham Biosciences, England) and 
exposed using the Chemidoc EQ system (Biorad). Proteins were quantified using 
Quantity One software version 9 (Biorad Laboratories, Hercules, CA, USA). 
 
5.2.4 Statistical Analysis 
Results are presented as mean ± SEM. Differences were determined using an 
unpaired t test and P values of <0.05 were considered significant.  
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5.3 Results 
5.3.1 Effect of γ-tocopherol on glucose uptake in L6 myotubes exposed to 
oxidative stress 
One hour treatment with 100 mU/mL glucose oxidase significantly decreased glucose 
uptake both with and without 100 nM insulin stimulation (Figure 5.1).  
 
 
Pre-treatment with 100 µM and 200 µM gamma tocopherol partially protected cells 
from the effect of glucose oxidase, where 200 µM gamma tocopherol restored both 
basal and insulin stimulated glucose transport to normal levels (Figure 5.1). 
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Figure 5.1 2-Deoxyglucose uptake in L6 myotubes that were differentiated as stated in 
methodology. Cells were treated for with 100 or 200 µM gamma-tocopherol (GT) for 24 hr, 
100 mU/mL glucose oxidase (GO) for 1 hr and 100 nM insulin for 30 min. * denotes 
difference between basal and insulin within a treatment, or both basal and insulin when 
compared to another treatment, P<0.05.  
* 
* 
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5.3.2 Insulin signalling in L6 myotubes exposed to oxidative stress and gamma 
tocopherol 
 
 
Figure 5.2 Phosphorylation of Akt serine-473 (A) and AS160 by Akt (B) relative to total β-
Actin in L6 myotubes that were differentiated as described in Methodology. Cells were 
treated for with 200 µM γ-tocopherol for 24 hr, 100 mU/ml glucose oxidase for 1 hr and 100 
nM insulin for 10 min. PAS: Phospho-Akt substrate. * denotes different to all other conditions, 
† denotes difference between treatments, P<0.05. 
 
0
20
40
60
80
100
120
VEH GO GT + GO
F
o
ld
 c
h
a
n
g
e
 v
e
rs
u
s
 b
a
s
a
l Basal
Insulin
B 
0
5
10
15
20
25
VEH GO GT + GO
F
o
ld
 c
h
a
n
g
e
 v
e
rs
u
s
 b
a
s
a
l
Basal
Insulin
* 
† 
† 
B-Actin 
PAS 
B-Actin 
(B) 
(A) Akt p-ser473 
  110
To assess whether the protective effect on basal and insulin-stimulated glucose 
transport of gamma tocopherol after induction of oxidative stress was due to 
improved signalling from the insulin receptor to GLUT4 vesicles, the phosphorylation 
of Akt and AS160 on amino-acid residues that are important for insulin signalling 
were assessed.  
 
Glucose oxidase did not impair basal or insulin stimulated phosphorylation of Akt or 
AS160, but 200 µM gamma tocopherol did improve insulin-stimulated 
phosphorylation of both Akt and AS160 and might partly explain the restoration of 
glucose transport in this condition (Figure 5.2). 
 
5.4 Discussion 
In the present study, we investigated the effects of gamma tocopherol on basal and 
insulin stimulated glucose transport  and insulin signalling in cultured rat L6 myotubes 
exposed to a H2O2 generating system. When the cells were exposed to oxidative 
stress using 100mU/ml glucose oxidase, glucose transport was impaired under both 
basal and insulin stimulated conditions. Pre-treatment with gamma tocopherol for 24 
h prevented this decrease in glucose uptake. In addition, we found that high (200 µM) 
but not low (100 µM) doses of gamma tocopherol restored glucose transport to 
normal levels; it also appeared to impact basal transport through mechanisms other 
than augmentation of insulin stimulated Akt or AS160 phosphorylation, because 
basal transport with 200 µM gamma tocopherol alone was not different from that 
when cells were treated with gamma tocopherol as well as stimulated with insulin. 
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Furthermore, neither basal Akt nor AS160 were impacted upon by 200 µM gamma 
tocopherol treatment. 
Our finding that H2O2 inhibits insulin-mediated glucose uptake is in agreement with 
some (Maddux et al., 2001, Hansen et al., 1999, Rudich et al., 1997)  but not all 
(Kozlovsky et al., 1997, Fischer et al., 1993, Evans et al., 2005, Timar et al., 1997). 
Discrepancies in result between the various studies can, in part, be explained by the 
differences in the experimental design, such as in vivo versus in vitro models and 
dose and duration of exposure to the compounds under investigation. Various levels 
of oxidative stress have been induced between 25-100 mU/mL glucose oxidase for 
periods varying between 5 min to 24hr. We found that the induction of H2O2  via 100 
mU/mL glucose oxidase for 1hr in L6 myotubes impaired insulin-stimulated glucose 
transport, in line with previous studies (Hansen et al., 1999, Rudich et al., 1997), but 
not the phosphorylation of Akt and AS160. Thus the precise mechanism by which 
ROS impairs glucose uptake has yet to be determined. Nevertheless improved 
glucose uptake and insulin signalling by pre-treatment with gamma tocopherol 
suggests this antioxidant plays some role in counteracting effect of oxidative stress. 
Disconnection between glucose transport and insulin signalling (i.e. Akt and AS160 
phosphorylation) in the current study strongly suggest that there are other 
mechanisms by which gamma tocopherol improved glucose transport. Given that the 
pre-treatment with gamma tocopherol was more prolonged than the glucose oxidase 
exposure, it is possible that reduced lipid peroxidation affords some improvement in 
the membrane dynamics and interaction of transporters such as GLUT4, or some 
other factor in the vicinity. The role of free radical attack in diabetes and in the 
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cardiovascular complications of the disease has been documented largely through 
the effects of free radicals on lipids and proteins (Giugliano et al., 1996, Oberley, 
1988, Ozdemirler et al., 1995). Gamma tocopherol has been shown to act on cell 
surface by preventing oxidation of LDL in cell membrane (Hodis et al., 2002). 
However, there is no evidence to suggest such mechanism exists to prevent ROS-
induced insulin resistance, and this is an area that requires further study. 
The mechanisms by which H2O2 and other mediators of oxidative stress cause 
insulin resistance are largely unknown. A possible explanation for the inhibitory effect 
of H2O2 on insulin action is that it triggers an alteration in cellular redox balance due 
to prolonged exposure. Stress inducers, including H2O2, can function as signalling 
molecules to activate a number of stress sensitive serine/threonine kinase pathways 
linked to insulin resistance (Evans et al., 2003). Insulin signalling enzymes offer a 
number of potential substrates for these activated serine kinases including the insulin 
receptor and the family of IRS proteins. Increased serine phosphorylation of IRS-1 
decreases the extent of insulin stimulated tyrosine phosphorylation and attenuates 
insulin action (Evans et al., 2002). Increased serine kinase activity that 
phosphorylates IRS-1 was identified in vitro and in vivo insulin resistance (Keren et 
al., 1997). Numerous agents that induce insulin resistance, such as TNF-α and other 
cytokines, platelet-derived growth factor, angiotensin, hyperinsulinemia, all increase 
IRS-1 serine phosphorylation (Sykiotis and Papavassiou, 2001) through induction of 
ROS (Nishikawa et al., 2007), which might explain their insulin de-sensitizing effects. 
The ability of gamma tocopherol to preserve the intracellular redox balance and 
prevent the activation of stress sensitive serine kinase cascades maybe instrumental 
in preventing the serine phosphorylation of IRS-1. Additional research which links the 
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activation of serine kinase cascades in oxidative stress induced insulin resistance is 
clearly warranted to firmly establish this link.  
In conclusion, we found that acute oxidative stress impaired glucose transport in Rat 
L6 myotubes. Pre-treatment with gamma tocopherol reversed the effect of oxidative 
stress and improved glucose uptake both in the absence and presence of insulin. 
However, disconnection between glucose uptake and the phosphorylation state of 
key proteins in the insulin signalling cascade suggest that gamma tocopherol 
improves glucose transport via insulin dependent and independent mechanisms. Our 
results suggest gamma tocopherol may play a preventive role in counteracting effect 
of oxidative stress on glucose uptake by skeletal muscle cells. Identification of the 
molecular basis for this observation might lead to the discovery of pharmacological 
targets for novel therapies to prevent, reverse or delay the onset of insulin resistance 
and resultant pathogenesis. 
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Chapter Six: Summary and Conclusions 
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The primary aim of the experiments undertaken in this thesis was to evaluate the 
efficacy by which various antioxidants may attenuate risk factors leading to 
thrombosis, atherosclerosis and other cardiovascular diseases under conditions of 
increased oxidative stress and the concomitant free radical production such as acute 
exercise, or hyperglycemia. Some of the most common risk factors of thrombosis 
leading to other cardiovascular disease are platelet hyperactivity and stickiness 
(Elwood et al., 1991), impaired lipid profile (Steinberg and Witzum, 1990), decreased 
glucose uptake and metabolism. All of these factors decrease available energy  
required for normal body functioning and contributes to disturbing redox balance 
between reactive oxygen species and antioxidants (Smith and Muscat, 2005). Many 
in vitro studies have shown that diet rich in fruits and vegetables act as effective 
antioxidant in biological systems such as blood cells, lipoproteins and cultured cells 
by inhibiting lipid oxidation in human plasma exposed to various patho or 
physiologically relevant types of oxidative stress. For that reason different 
antioxidants commonly consumed as part of a regular diet, including olive leaf by 
Mediterranean population in particular, cocoa and gamma tocopherol (one of the 
vitamin E isoforms) were examined with respect to their potential to prevent 
thrombosis by improving platelet function, lipid profile or glucose transport in two 
intervention and two in vitro studies undertaken for this thesis. 
 
A direct link has been demonstrated between Mediterranean diet rich in olives and 
olive oil and lower incidence of cardiovascular diseases. Although olive oil is rich in 
antioxidants, olive leaf extract has been shown to have even more potent antioxidant 
properties. Olive leaves have been traditionally used to make tea in routine for 
medicinal purposes in some Mediterranean countries for centuries. The first study, 
presented in chapter two, determined that 54 µg/mL olive leaf extract was effective in 
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improving platelet function by reducing platelet aggregation and ATP released from 
activated platelets. Lower ATP release by platelets in response to physiological 
agonist stimulation suggests olive leaf extract may be instrumental in attenuating 
platelet activity and thus preventing risk of thrombosis, atherosclerosis and other 
cardiovascular disease. These results provide novel information with respect to a 
potential mechanism by which olive leaf extracts reduces risk of cardiovascular 
diseases. The results of this study provide the first evidence that olive leaf extract 
treatment might be able to improve platelet function in normal healthy population.  
 
In light of these findings, the next study, described in chapter three, was designed to 
evaluate platelet activity in response to increased oxidative stress and to examine the 
effect of antioxidant supplementation on markers of platelet function. Platelet activity 
has been shown to increase in response to exercise by various studies. This has 
been attributed to increased production of reactive oxygen species and other free 
radicals during exercise.  It has also been suggested that sudden acute exercise 
poses increased risk of CVD (Wang, 2006). On the other hand chronic exercise is 
considered therapeutic in prevention of CVD. It seemed likely that the platelet 
response to acute exercise would differ in the trained versus sedentary individuals 
and that antioxidant supplementation may be able to attenuate the increase in 
platelet activity induced by exercise.  
 
Accordingly, the study presented in chapter three compared platelet response to an 
acute bout of submaximal exercise between trained and sedentary subjects both 
before and after short term cocoa polyphenol supplementation. The results of this 
study demonstrated that regular training increased platelet number but resulted in 
lower stimulated platelet activity and aggregation compared to sedentary subjects in 
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response to standardised exercise undertaken before and after 1 wk period of cocoa 
supplementation. Higher platelet number has been linked to an increased chance of 
platelet aggregation under shear stress. However, the increased rate of aggregation 
with lower number of platelets in sedentary subject indicates that a single bout of 
submaximal exercise may be resulting in increased production of free radicals in 
sedentary subjects more than in trained individuals, or, conversely, that regular 
exercise training could improve endogenous antioxidant defence (Wilson and 
Tanaka, 2000, Ji, 2001). It has been shown that antioxidant enzyme activity is 
stimulated by acute exercise, which could be part of defence mechanism of cells 
against oxidative stress (Belviranli and Gokbel, 2006). There is insufficient 
information about relationship of exercise and antioxidants. However, short term 
supplementation with cocoa polyphenol was not enough to counteract the effect of 
acute sudden exercise on platelet activity in sedentary population. The results of this 
study suggest that the risk of thrombosis is probably greater in untrained subjects 
participating in a single bout of exercise, and that short term cocoa supplementation 
was not enough to combat effect of increased reactive oxygen species production in 
sedentary population. These findings warrant for further studies with long term 
antioxidant supplementation.  
 
Olive leaf extract and cocoa polyphenols used in the two previous studies are both 
hydrophilic antioxidants. So the next step was to assess if effect of a lipophilic 
antioxidant is also equally important in preventing risk of thrombosis. Gamma 
tocopherol (vitamin E), a lipophilic antioxidant, has been inversely related to risk of 
cardiovascular disease. Almost all of the trials used alpha tocopherol form of vitamin 
E but the predominant form of vitamin E found in food is gamma tocopherol. It has 
been demonstrated that supplementation with alpha tocopherol reduces the effect of 
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gamma tocopherol. Thus it makes sense to increase gamma tocopherol 
supplementation or not to disturb the balance between alpha and gamma tocopherol 
intake as found in natural dietary plant sources. 
 
Based on this fact it seems more likely that gamma tocopherol would be more 
effective in preventing atherogenesis. One of the primary steps of atherogenesis is 
endothelial dysfunction which results in reduced nitric oxide generation. At the same 
time free radicals like superoxide react with nitric oxide producing peroxynitrile, thus 
reducing bioavailability of nitric oxide. Given the potential of gamma tocopherol in 
neutralising reactive nitrogen species more potently, the clinical trial described in 
chapter four supplemented normal healthy subject’s diet with two different doses of 
gamma tocopherol. The results of this study provide first evidence of the preventive 
effect of pure gamma tocopherol on risks of thrombosis by improving lipid profile that 
is less LDL cholesterol for oxidation and less foam cell formation. Decreasing mean 
platelet volume as well as platelet activity and aggregation on stimulation with 
agonists can all be instrumental in attenuating risk factors of thrombosis. These 
results provided evidence for distinct role of gamma tocopherol in preventing risk 
factors leading to thrombosis and other CVD in normal healthy population.  
 
In light of these findings in vitro cell culture experiments (chapter five) evaluated the 
effect of gamma tocopherol under conditions of increased oxidative stress.  Insulin-
stimulated glucose uptake by skeletal muscle under conditions such as 
hyperglycemia in diabetes is impaired due to the presence and action of free 
radicals. The results of this study demonstrated that gamma tocopherol reversed the 
effect of oxidative stress on insulin stimulated glucose uptake and increased 
expression of Akt (Ser 473) and AS160 in Rat L6 skeletal muscle myotubes. However, 
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unlike glucose uptake, the expression of Akt (Ser 473) and AS160 did not change 
when myotubes were exposed only to glucose oxidase-induced oxidative stress. This 
study provides novel information with respect to a potential mechanism by which 
glucose transport may be facilitated by gamma tocopherol. Increased expression of 
Akt (Ser 473) and AS160 in conjunction with increased insulin stimulated glucose 
uptake by skeletal muscle myotubes after treatment with gamma tocopherol 
demonstrate that gamma tocopherol is instrumental in improving glucose transport 
under oxidative stress conditions. These results suggest that there may also be some 
other mechanisms also involved by which gamma tocopherol reverses glucose 
uptake by oxidised myotubes. Further investigation into the effect of gamma 
tocopherol and other antioxidants on various signalling proteins of insulin signalling 
pathway and other mechanisms are needed. 
 
In summary, the results from the studies undertaken for this thesis provide novel 
information regarding the role of various hydrophilic and lipophilic antioxidant 
supplementations in potentially preventing cardiovascular disease through 
mechanisms involved in platelet activation and aggregation and glucose transport 
under conditions of oxidative stress. Antioxidant supplementation particularly under 
high oxidative stress conditions is likely to play a preventive role in reducing risk of 
thrombosis and other related complications leading to CVD. Incorporating a balance 
of natural antioxidants in the diet and incorporating regular exercise into daily living 
may be able to improve general public health. Results from these studies support the 
hypothesis that various dietary sources of antioxidants including foods rich in cocoa, 
olive and gamma tocopherol are instrumental in combating oxidative stress induced 
cardiovascular diseases. Antioxidant supplementation may show potential health 
benefits by reducing risk of thrombosis and thus indirectly improving quality of life, 
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reducing pain and the potential costs of disease treatment particularly by preventing, 
life style mediated conditions leading to diabetes, thrombosis and as a consequence 
other cardiovascular diseases. 
 
 
Several important questions should be addressed in future work. For example, what 
are most appropriate doses and durations for antioxidants alone or in combination to 
be effective in preventing risk of conditions leading to CVD? In addition, future work 
should determine the mechanisms by which oxidative stress impairs platelet activity, 
lipid profile and glucose transport. Such information may provide clues for the 
development of more effective preventive as well as therapeutic antioxidant agents 
from natural food sources that specifically target platelets, endothelial wall and 
skeletal muscle maintenance. Further studies should include comparative and 
synergistic effect of various doses of alpha tocopherol and gamma tocopherol in 
humans with and without oxidative stress on mechanisms of platelet activity as well 
as other thrombotic coagulation markers and mechanisms leading to glucose uptake. 
 
Continued research into various antioxidants and the mechanisms by which they act 
to overcome the impairments of CVD may lead to establishing more effective doses 
necessary in preventing progress of asymptomatic atherosclerosis to CVD. Given the 
increasing prevalence of sedentary life style, obesity, diabetes (all of which show 
increased oxidative stress) and CVD universally, it seems research in this field has a 
long way to go. One area of interest will be comparing antiplatelet therapies with 
antioxidant supplementation in normal healthy subjects and diabetic subjects. 
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